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ABSTRACT OF THE DISSERTATION
Escherichia coli Iron Acquisition Paradigms
and Host Responses in the Human Urinary Milieu
by
Robin R. Shields-Cutler
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2015
Professor Jeffrey P. Henderson, Chair

Urinary tract infections (UTIs) are some of the most common bacterial infections worldwide and
are increasingly complicated by high antibiotic resistance and recurrence rates. Explanations for
the marked individual differences in UTI susceptibility remain incomplete. In this thesis we
show that urinary colonization by uropathogenic E. coli (UPEC) is influenced by urine
composition and the activity of an important innate immune protein, siderocalin (SCN; also
called lipocalin 2 or neutrophil gelatinase-associated lipocalin/NGAL). During UTI, host factors
limit the availability of iron, an essential nutrient for the invading pathogen. In response, UPEC
modify the urinary environment with metal binding siderophores, some of which are bound by
the soluble protein SCN. Interactions between these opposing factors during early UPEC
colonization determine the pathogen’s ability to successfully acquire iron and grow to a density
sufficient to cause infection.

viii

SCN has been described at length as an antimicrobial protein, exerting its effect by sequestering
certain ferric siderophores. This has led to the hypothesis that a pathogen’s additional, non-SCNbinding siderophores are adaptations to this host pressure; however, the role of individual
siderophores has been shown in some models to depend greatly on the infection environment.
Because human urine is chemically complex and distinct from other sites of infection, we first
investigated SCN’s effect on uropathogenic E. coli (UPEC) growth in human urine from a
healthy reference population. Using genetic deletions, chemical inhibition, and chemical
complementation, we observed enterobactin siderophore expression to be a key factor permitting
UPEC growth in SCN-supplemented human urine from a subset of individuals. Because SCN
neutralizes enterobactin in non-urinary experimental systems, this result suggests a determinative
role for urine-specific components in manipulating antimicrobial paradigms.

Our initial inquiry showed dramatic variability in SCN’s antimicrobial activity between
individuals’ urine specimens. We next used these individual differences as an independent
variable, defining groups of high and low activity, in order to investigate the urinary factors
controlling SCN activity. Chemical and demographic comparisons yielded a significant positive
correlation between SCN activity and elevated urine pH. To determine whether further
individual differences arose from differences in urinary small molecule composition (the urinary
metabolome), we compared individuals using a mass spectrometry-based metabolomic approach.
This approach identified aryl alcohols as significant correlates with SCN activity. These results
support a model in which the urinary environment is able to influence urinary tract colonization
by pathogens.
ix

To further understand how these urinary metabolites may contribute to SCN antimicrobial
activity, we sought to identify key metabolite cofactors present in restrictive urine specimens that
actively participate in SCN’s antimicrobial mechanism as observed above. We developed a
robust biophysical screen that allowed us to look for urine fractions containing iron-dependent
SCN ligands. A biophysical validation process identified several elevated aryl alcohols that
bound SCN and were able to reconstitute SCN’s antimicrobial activity in simple, defined media
with limited iron. Demonstrating that urinary metabolites confer elevated SCN activity in a
defined media provides mechanistic validation for our proposed urinary model, and further
supports a dietary component to preventative UTI therapies. The human metabolome may thus
represent an underappreciated contributor to disease susceptibility and pathogen evolution, and a
potential target for future therapeutic interventions.

Collectively, the work presented in this thesis describes an emerging host-pathogen axis, where
urinary composition plays a pivotal role in the efficacy of an innate immune response, and
suggests targeted avenues for improved clinical control of UTI.
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CHAPTER ONE

Introduction: Bacterial iron acquisition and the host’s response during UTI

1

1.1 Clinical challenges of urinary tract infections
Urinary tract infections (UTIs) are one of the world’s most common infectious diseases.
Approximately half of all women will have experienced at least one UTI episode by their mid30s (1, 2). Young children and the elderly also experience UTI with higher frequency, as do
hospital inpatients with indwelling urinary catheters (1, 3). The typical pathogenic course for
UTI begins when periurethral bacteria—most commonly Escherichia coli—colonize the bladder
and then invade the epithelial cells and replicate, eventually leading to the inflammation
responsible for UTI’s major symptoms (2, 4, 5). Serious infections occur when bacteria ascend
the ureters and access the kidney, causing an infection called pyelonephritis (3). From the
kidney, bacteria may then infect the bloodstream, causing urinary-source bacteremia, a
potentially life-threatening disease (3). Historically, UTI has been treated empirically with
standard antibiotics but uropathogens are increasingly resistant to these drugs, creating
therapeutic challenges that place a significant physical and financial burden on the healthcare
system, and notably decrease patients’ quality of life (1, 2, 6, 7).

In addition to the challenges of resistant infections, roughly one quarter of women with
uncomplicated UTIs will go on to experience a recurrent infection within six months (8). These
recurrent infections, often caused by the same strain, may happen as frequently as 5-10 episodes
per year, which causes considerable morbidity and discomfort, and present unique challenges to
developing preventative therapies (9). One challenge faced in treating UTI is heterogeneity in
disease progression, where some individuals experience a single self-resolving cystitis episode,
while others progress to highly recurrent or even life-threatening systemic infections (2, 10–12).
Patient stratification could improve antibiotic stewardship and explorations into alternative
2

therapy, but individuals’ wide-ranging susceptibilities to infection and recurrence are poorly
understood.

As precision medicine becomes common in other fields, it is important to consider that host
differences may also play determinative roles in infectious disease susceptibility and in responses
to particular therapies (13–15). Currently, prophylactic antibiotics are commonly prescribed to
limit recurrences, but this carries significant side effects and disadvantages, including selective
pressure on pathogens and commensals for antibiotic resistance (2, 16). Therefore, reducing the
reliance on traditional antibiotics has myriad advantages, including avoiding collateral damage to
the host’s commensal microbiota and slowing the emergence and spread of antibiotic resistant
pathogens (16–18). Non-antibiotic therapies to prevent recurrent UTI have been explored but are
largely inconsistent and poorly studied (2, 6, 19). Additional research on pathogen mechanismand virulence-targeted therapies may provide novel avenues for effective treatments.

1.2 Iron sequestration at the host-pathogen interface
One of the most fundamental host responses to bacterial infection is micronutrient restriction (20,
21). When a bacterial infection is recognized, transcriptional responses rapidly produce, among
many other effectors, proteins charged with limiting available concentrations of essential
nutrients such as transition metals (22–24). The conflict over nutrient iron, in particular, is a
major feature of both host and pathogen behavior during infection (25–27). During an infection,
upregulation of host iron transport and storage factors drives the free iron concentration in the
serum to an astonishing ~10-24 M (28–30). This nutritional response is a key aspect of innate

3

immunity, and deficiencies or abnormalities in iron regulation are linked with a number of
pathologies including susceptibility to infectious diseases (21, 31–33).

Iron restriction creates an environment where pathogenic bacteria require active processes to
acquire iron in order to replicate. While the infection milieu may contain ~10-24 M iron, bacterial
cells demand on the order of 10-6 M iron for basic physiology and metabolism (34). To overcome
this vast discrepancy, pathogens have evolved multiple virulence factors dedicated to acquiring
iron from host proteins such as transferrin or ferritin, or iron-containing cofactors such as heme
(30). The importance of this process is emphasized by the diversity and redundancy present in
Gram-negative bacterial iron acquisition, and underscores their potential as targets for antivirulence approaches (35, 36).

In order to compete with the host factors upregulated during infection, Gram-negative pathogens
like E. coli have evolved small molecule (<1.5 kDa), high-affinity iron chelators, called
siderophores (Fig. 1a). Diverse organisms produce an equally diverse collection of siderophores
(36), while this thesis specifically investigates the virulence-associated subset of siderophores
expressed by uropathogenic E. coli (UPEC). Multiple genetic and phenotypic screens confirm
that UPEC produce up to four siderophores (Fig. 2): the conserved catecholate siderophore
enterobactin; the glucosylated enterobactins or salmochelins; the mixed hydroxamate-phenolate,
yersiniabactin; and the citrate-hydroxamate, aerobactin (37–39). Each siderophore possesses
unique physiochemical properties and genotypic frequencies, suggesting specialized roles for
pathogenesis (36, 40).

4

Siderophores successfully circumvent host iron sequestration due to their incredible iron affinity
(Fig. 1b), with pH-dependent stability constants of up to 1049 for enterobactin (41). Transferrin,
on the other hand, binds two molecules of iron with stability constants of ~1022 at pH 7.4 (28).
Numerous studies have demonstrated these siderophores’ ability to capture iron from transferrin,
lactoferrin, and ferritin, though the process is often kinetically slow and pH-dependent (42–45).
During UTI, iron limitation in the tissue and urine relieves transcriptional repression by the Fur
regulator, leading to upregulated expression of siderophore operons (36, 46, 47). These
secondary metabolites are synthesized from common metabolic precursors such as chorismate
and amino acids, and are assembled by non-ribosomal peptide and/or polyketide synthases (36).
This process consumes valuable biosynthetic precursors and can make a measurable impact on
the pathogen’s metabolism (48). Producing multiple factors at a notable cost to accomplish the
same goal—iron acquisition from the host—suggests that the chemical diversity in siderophore
structures provides fitness benefits in varying host environments. This has been demonstrated in
lung models of Klebsiella pneumoniae infection (49), and in the copper-binding and superoxide
dismutase activity of yersiniabactin during UTI (50, 51). In addition, expressing multiple
siderophores has been hypothesized as a means of evading the host immune response, namely
sequestration by the protein siderocalin (or lipocalin 2, neutrophil gelatinase-associated
lipocalin/NGAL, 24p3) (52–54). This thesis further examines this hypothesis, investigating the
roles of UPEC siderophores in acquiring iron from the human urinary environment in the
presence of the innate immune protein siderocalin.

5

1.3 Siderocalin’s Antimicrobial Activity
Siderocalin (SCN), also commonly called lipocalin 2 or neutrophil gelatinase-associated
lipocalin (NGAL), is a member of the lipocalin protein family (55, 56). An 8-stranded β-barrel
fold defines these soluble proteins, and also shapes the proteins’ binding sites (Fig. 3a,b); typical
ligands for these sites are small hydrophobic molecules. SCN was discovered by Kjeldsen and
colleagues when it was co-purified with gelatinase from human neutrophils (57–59), but its
function and ligand(s) would remain unknown for nearly a decade. In 2002, Goetz and
colleagues published a seminal paper presenting SCN’s crystal structure, showing that when
purified from certain E. coli strains, the binding site (or calyx) was occupied with an iron atom
chelated by a small molecule (60). They showed that the ligand was in fact ferric enterobactin,
the common E. coli siderophore (29, 37, 60). When coordinated with Fe(III), enterobactin carries
a delocalized net -3 charge. The SCN calyx is shaped by Lys125, Lys134, and Arg81, creating a
positively-charged pocket that stabilizes the ferric enterobactin complex with sub-nanomolar
affinity at physiologic pH (Fig 3c,d) (60, 61). This serendipitous discovery lead to the hypothesis
that SCN’s role is to sequester ferric siderophores during infection (Fig. 1b), a proposal
consistent with its abundance in neutrophil granules and upregulation in response to a number of
infectious challenges (58, 60, 62, 63). In accordance with other lipocalin protein names, which
are derived from their ligand, NGAL was re-named siderocalin (60).

Subsequent work by multiple laboratories has supported SCN’s role in preventing bacterial iron
acquisition. SCN has been implicated in the pathogenesis of E. coli, K. pneumoniae,
Mycobacterium

tuberculosis,

Vibrio

cholerae,

Streptococcus

pneumoniae,

Chlamydia

pneumoniae, Salmonella enterica, and Pseudomonas aeruginosa, for example (62, 64–67). For
6

most of these successful human pathogens, evading iron sequestration by SCN appears to be a
factor driving virulence factor adaptation. Work in Salmonella first suggested that the
salmochelins, or glucosylated enterobactins, produced by the iroA gene cluster were virulenceassociated adaptations to overcome SCN (53, 68). Adding glucose moieties to linearized
enterobactin’s catecholate groups increases the siderophore’s solubility and the bulky additions
block binding in SCN’s calyx, thus preventing SCN from sequestering the ferric salmochelin
siderophore (40, 53). Similar stories describing “stealth” or “escape” siderophore behavior have
since emerged for other pathogens including E. coli, K. pneumoniae, and M. tuberculosis (54, 65,
69). In these examples, pathogens maintain and express both SCN-sensitive and SCN-insensitive
siderophores. As a result of these characterizations, SCN evasion has become a common
explanation for encoding multiple iron-chelating secondary metabolites, despite the metabolic
cost (36, 52, 70). This parallels the evidence that UPEC siderophore biosynthesis is highly
upregulated and important for UTI pathogenesis (38, 39, 71–74).

Previous murine studies indicate that SCN is highly upregulated in UPEC-infected bladder tissue
(71). Recently, several studies including one presented in this thesis showed that SCN is found at
elevated levels in the urine of women with UTI, and another study proposed its use as a
biomarker for pediatric UTI (72, 75–77). The high local SCN concentration during UTI—up to
10 µM in unfractionated urine (72)—likely derives from the characteristic neutrophil recruitment
and inflammation in the bladder, neutrophils present in the urine, and epithelial cell secretion
(78, 79). Specific cell types in the kidney are also implicated in SCN secretion (72). These data
all point to SCN’s involvement in the host response to E. coli UTI, however its role and efficacy
as an iron-sequestering antimicrobial protein in this environment has been unclear, and is the
7

focus of this thesis. This question is particularly interesting, as UPEC isolates express an
assortment of siderophores, possessing anywhere from one to four distinct siderophore pathways
(37). Whether this diversity is driven by SCN or whether it has any relevant implications at all
was unknown.

1.4 The SCN ligand dilemma
A careful reading of the SCN antimicrobial literature suggests that there is more to its story than
“stealth” siderophores. Interestingly, a K. pneumoniae mutant lacking enterobactin biosynthesis
(but capable of yersiniabactin biosynthesis) was inhibited by SCN in pooled urine, but not in
RPMI media (65). This effect was noted only because some of the clinical isolates were obtained
from urine; since the paper studied virulence factors in respiratory infection, this curious paradox
was left untested and unaddressed. However, when this enterobactin-deficient strain was used to
infect SCN-deficient transgenic mice, the animals tended to fare worse than their wild type,
SCN+/+ counterparts. In both these subtle examples, SCN displayed a protective effect despite the
absence of any known bacterial siderophore ligand. Separately, some studies have suggested that
Gram-negative bacteria can access iron bound by small aromatic metabolites of the host (80–85),
due to their chemical similarity to siderophores and intermediates. Combined, these findings
raised the question of whether SCN could participate in iron sequestration independent from
bacterial ligands such as enterobactin.

Bao and colleagues presented an important perspective on this question by testing human
metabolites’ ability to bind SCN as ferric complexes (86). They established that SCN could
indeed interact with ferric complexes other than bacterial siderophores and identified several
8

common catecholates as potential endogenous ferric ligands of SCN. These metabolites are
structurally similar to the prototypic ligand, enterobactin, and chelate iron in the same
hexadentate coordination, thus mimicking ferric enterobactin’s shape and overall negative charge
arrangement. This enables high-affinity binding in the SCN calyx, and stabilization by the same
cation-π and electrostatic interactions as enterobactin (60, 87, 88). Furthermore, it appears that
while these free ferric-catecholate complexes are transient and labile in solution, the SCN calyx
provides a molecular template that drives formation of stable ferric complexes within the binding
site (86). The authors then showed that the SCN-catecholate complex is stable when injected into
mice, and proposed that this serves as yet another means of iron regulation and trafficking within
mammalian host serum and tissues. Since they tested a limited number of pure metabolites from
a commercial pool, there are likely additional potential ligands present in various host
microenvironments with important physiochemical properties. Furthermore, although the
biophysical details were thoroughly investigated, it was unclear whether these metabolite
interactions truly contribute to SCN’s role in any specific disease or metabolic process.

1.5 Questions and hypotheses
Curiously, while SCN’s discovery and subsequent biochemical characterizations have focused
on its antimicrobial roles, the SCN literature has been largely populated by studies unrelated to
bacterial pathogenesis. As of this thesis’ submission, a PubMed search for SCN (including its
common aliases) yields nearly 2,000 articles; adding “bacteria” to the search term reduces this to
just 61 publications. Since SCN is upregulated in response to general inflammatory stimuli, is
found at relatively high levels in biofluids, and is relatively stable, it has been proposed as a
biomarker for ailments ranging from acute kidney injury to late-life depression (89–91).
9

Correlative studies have also suggested its involvement in diseases such as breast cancer and
diabetes (92–94). Mechanistic evidence in these associations is notably absent, however, and the
question remains in what endogenous interactions and activities SCN might engage, in the
absence of a bacterial ligand.

Together, early observations about SCN’s interactions with endogenous metabolites and its
perceived involvement in myriad host processes suggest functional consequences for this protein
that have been previously unappreciated. Because SCN is upregulated during UTI (71, 77) and
diet-derived host catecholates are known components of urine (95), we hypothesized that
interactions between these components would affect SCN’s anti-UPEC activity in urine, and
could be relevant to UTI pathogenesis. Since all previous literature on SCN’s activity, the
consequences of interactions with host molecules, and the relationship between SCN and
multiple bacterial siderophores had been carried out in non-urinary contexts, the specific and
unique effect of urinary composition on SCN’s activity is a compelling but unaddressed
question, prior to the work presented in this thesis. We hypothesized that by sequestering iron in
host-derived complexes SCN can limit bacterial growth, regardless of siderophore compatibility,
by preventing access to the urine’s bioavailable iron.

This thesis therefore investigates whether SCN’s interactions with urinary cofactors can control
UPEC growth, and whether certain siderophores are necessary to overcome this inhibition. Our
investigations are guided by the following basic questions:

1. Does SCN restrict UPEC growth in human urine?
2. Do particular UPEC siderophores provide competitive advantages in the presence of SCN?
10

3. Do unique features of human urine play deterministic roles in SCN’s antimicrobial activity?
4. If SCN does exhibit anti-UPEC activity, can human urine be manipulated to potentiate this
effect?

These questions span the fields of basic biology, biophysical chemistry, and clinical medicine.
To reconcile wide-ranging hypotheses, this thesis combines basic microbiology with biochemical
observations made from individual human specimens. By recognizing patterns in SCN activity,
we developed sensitive chemical analyses to identify host and microbial correlates to explain the
differences between individual responses to UPEC infection (77). Biochemical and biophysical
methods were also used to define the chemical players that ultimately determine SCN’s activity.
The findings of this thesis have important clinical implications for UTI patients, particularly
those with susceptibility to frequent UTI.

11

CHAPTER ONE: FIGURES

Figure 1. Siderophore-based iron acquisition by pathogenic E. coli. (a) E. coli bacteria (in
brown) secrete siderophores (blue, yellow, and green shapes) to chelate ferric iron (red
hexagons) from the environment. These small molecule chelators are then imported by specific
receptors on the bacterial outer membrane (matching shapes on bacterial surface). To obtain
essential iron in the context of a mammalian host (b), pathogenic E. coli secrete siderophores
that effectively compete with host iron binding factors such as ferritin (in green), transferrin (in
purple), and host metabolites (shown as a 3:1 ferric complex). The innate immune protein
siderocalin (SCN, in blue) can counteract this process by sequestering some ferric-bound
siderophores in its binding site. The extent to which SCN can inhibit bacterial iron uptake may
be determined by the siderophores’ chemical structures as well as the infection
microenvironment.
12

Figure 2. UPEC produce several chemically distinct siderophores. UPEC isolates possess
biosynthetic machinery to make varying combinations of the four siderophores depicted above,
with the exception of enterobactin, which is ubiquitously expressed by UPEC.

13

Figure 3. Siderocalin’s tertiary structure and binding site. (a) Siderocalin displays the typical
8-stranded β-barrel lipocalin fold; the antiparallel sheets form the binding site viewed from the
14

top in (b). Residues Lys125, Lys134, and Arg81 give the binding site its critical positive charge,
and are indicated as sticks in (a) and (b). The interaction between SCN and enterobactin is
modeled in (c) using a non-hydrolyzable enterobactin analog, Fe(TrenCam). (d) On left, the
wild-type SCN calyx is shown with calyx lysine residues in purple; on right, the K125A/K134A
mutant calyx is shown with the substituted alanine residues in purple. Wild-type SCN PDB ID:
3HWF. Mutant SCN PDB ID: 3HWD.

15
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CHAPTER TWO

Human Urinary Composition Controls Antibacterial Activity of Siderocalin
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ABSTRACT
During Escherichia coli urinary tract infections, cells in the human urinary tract release the
antimicrobial protein siderocalin (SCN; also known as lipocalin 2, neutrophil gelatinaseassociated lipocalin/NGAL, or 24p3). SCN can interfere with E. coli iron acquisition by
sequestering ferric iron complexes with enterobactin, the conserved E. coli siderophore. Here we
find that human urinary constituents can reverse this relationship, instead making enterobactin
critical for overcoming SCN-mediated growth restriction. Urinary control of SCN activity
exhibits wide ranging individual differences. We used these differences to identify elevated
urinary pH and aryl metabolites as key biochemical host factors controlling urinary SCN activity.
These aryl metabolites are well-known products of intestinal microbial metabolism. Together,
these results identify an innate antibacterial immune interaction that is critically dependent upon
individualistic chemical features of human urine.
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INTRODUCTION
Escherichia coli are the predominant cause of urinary tract infections (UTIs)5, one of the world’s
most common bacterial infections (1). Compared to familiar K12 strains, uropathogenic E. coli
(UPEC) secrete an expanded repertoire of siderophores, low molecular weight metal ion
chelators defined by their ability to scavenge Fe(III) for nutritional purposes (2, 3). Siderophore
biosynthetic genes are dramatically upregulated during experimental UTI and a UPEC
siderophore has been directly detected in urine from UTI patients using mass spectrometry (4–6).
Genes encoding the enterobactin siderophore system are ubiquitous in E. coli, while the nonconserved yersiniabactin, salmochelin, and aerobactin systems exist in varying combinations (2).
Expression of different siderophore types exacts varying metabolic costs that may affect each
siderophore system’s frequency within a population (7).

The evolutionary circumstances that have led UPEC to express multiple siderophore systems are
incompletely understood. Differential susceptibility to sequestration by the innate immune
defense protein siderocalin (SCN; also known as lipocalin 2/LCN2, neutrophil gelatinaseassociated lipocalin/NGAL, or 24p3) has been proposed as a major selective pressure driving
acquisition of chemically diverse, virulence-associated UPEC siderophores (8–10). SCN is
introduced into the urinary tract by neutrophil granules and uroepithelial cells, which upregulate
SCN >100-fold within 24 hours of bladder inoculation (4). SCN can restrict iron accessibility by
binding Fe(III) complexes with high affinity within the protein’s positively charged binding site,
or calyx (11, 12). While enterobactin is the prototypical ferric ligand in these complexes, other
siderophore and non-siderophore ligands have been described and substantiated in detailed
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binding and crystallographic studies (12, 13).

Here, we used genetic and chemical approaches to determine how UPEC siderophores and SCN
interact in the chemically distinctive urinary environment associated with human UTIs. We
found that human urinary constituents make enterobactin critically important for resisting SCN,
in contrast to its role as a SCN target in non-urinary environments (8, 14, 15). Individual
differences in urinary properties allowed us to chemically dissect urinary composition, revealing
pH and aryl alcohol metabolites as critical SCN antibacterial activity correlates. These results
point to the existence of a urinary tract-specific host-pathogen interaction system involving
siderocalin, host metabolites, and bacterial enterobactin biosynthesis. These findings suggest
non-antibiotic chemical therapeutic strategies that potentiate innate antibacterial defenses against
urinary pathogens.
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EXPERIMENTAL PROCEDURES
Bacterial strains and media. We used the well-characterized E. coli uncomplicated UTI isolate
UTI89 as the model uropathogenic E. coli strain in our studies. Cultures were grown from single
colonies in Difco Luria-Bertani (LB; BD, Franklin Lakes, NJ) broth for 4-6 hours at 37°C.
Isogenic siderophore biosynthesis mutants were constructed as in-frame deletions in UTI89
using the lambda Red recombinase method as previously described (2, 16, 17).

Human urine collection. Healthy donor urine was obtained from adult volunteers as approved by
the Institutional Review Board of Washington University School of Medicine. Participants
provided written informed consent for collection of up to two specimens, at least one week apart,
for subsequent discovery and validation analyses. Exclusion criteria included recent UTI,
antibiotic therapy, pregnancy, or any urogenital disease. To avoid donors with asymptomatic
bacteriuria, urines were tested for growth on MacConkey II agar and TrypticaseTM soy agar with
5% sheep blood (BD). Urines were filter sterilized and stored at -80°C until use. For experiments
on pooled urine, equal volumes of individuals’ urines were mixed. One specimen was excluded
because it did not support E. coli growth in vitro.

Cystitis urine collection. Urine specimens from subjects with E. coli cystitis were chosen from
among samples collected in a prospective cohort study of immunological and other pathogenic
factors in recurrent UTI conducted between 2008 and 2012 among 326 pre-menopausal women
presenting with acute, uncomplicated cystitis at the University of Washington Hall Health
Primary Care Center. Women were eligible if they were aged 18-49 years, in good general
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health, and had fewer than 7 days of typical symptoms of acute cystitis per standard clinical
definitions (dysuria, frequency, and/or urgency) (18). Exclusion criteria included signs or
symptoms of pyelonephritis, chronic illness requiring medical supervision, known anatomic or
functional abnormalities of the urinary tract, urinary catheterization, UTI within the preceding
month, current or planned pregnancy within 3 months or non-use of contraceptives. The urine
specimens examined here (n = 19) were obtained from subjects’ initial visits with the diagnosis
of E. coli acute uncomplicated cystitis with ≥105 CFU/mL of a beta hemolytic isolate. The
Human Subjects Review Committee of the University of Washington approved the study, and all
subjects gave written informed consent. One-tenth volume of Sigma FAST protease inhibitor
solution (Sigma) was added to freshly voided urines before clinical centrifugation to remove
cellular material, and the supernatant was frozen at −80 °C until use in the study.

Protein production. SCN constructs (human SCN, the kind gift of Dr. Roland Strong; mouse
SCN, the kind gift of Dr. Jonathan Barasch) were expressed in the BL21 E. coli strain,
essentially as described (11, 13). Briefly, GST-tagged SCN protein was expressed on a pGEX4T
vector (GE Healthcare, Fairfield, CT); we used Pierce glutathione agarose (Thermo Fisher
Scientific, Rockford, IL) to affinity purify GST-SCN, digested on-column with thrombin (Sigma,
St. Louis, MO) to liberate free SCN, and removed thrombin with p-aminobenzamidine agarose
(Sigma). Mutant K125A/K134A human SCN (the kind gift of Dr. Roland Strong) was expressed
periplasmically on a pET22b vector with a 6His-tag, purified on TALON cobalt affinity resin
(Clontech, Mountain View, CA), and eluted with 200 mM imizadole (Sigma). SCN protein
products were extensively desalted or dialyzed to 1X PBS and concentrated on 10 kDa cut-off
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Centricon filters (EMD Millipore, Billerica, MA); protein purity was monitored and confirmed
by SDS-PAGE, UV-Vis spectroscopy, and mass spectrometry. Similar conformation and folding
between wild type and mutant SCN proteins was confirmed by identical circular dichroism
spectra (Jasco J-810 spectropolarimeter, Easton, MD) and thermal denaturation profiles.

Urinary chemical characterization. Urine specific gravity was measured by urine refractometer
(ATAGO, Bellevue, WA), pH was determined by pH probe (Denver Instruments, Bohemia,
NY), and we used DiaScreen urinalysis dipstrips (Arkray, Edina, MN) for detection of ketones,
urobilinogen, bilirubin, protein, glucose, nitrite, leukocytes, and blood. Urine metal content was
determined by inductively coupled plasma-optical emission spectroscopy (ICP-OES) on a Perkin
Elmer Optima 7300DV instrument, by the Nano Research Facility at Washington University in
St. Louis, Department of Energy, Environmental and Chemical Engineering. Quantification was
achieved using calibration standards at 5, 10, 20, and 100 µg/L iron; and 1, 5, 10, 50, and 100
µg/L for other metals. Urine samples were diluted 1:10 in trace-metal grade nitric acid (Fisher
Scientific, Fairlawn, NJ) with a final acid concentration of 2% HNO3 and analyzed in triplicate.

Urinary SCN ELISA. Urine SCN concentration was determined by commercial ELISA
(BioPorto, Thermo Fisher Scientific). Cystitis and healthy control urines were processed and
diluted according to the manufacturer’s instructions, and the calibration curve was fit and
interpolated using Prism v. 6.0d (GraphPad, San Diego, CA).

36

SCN growth assay. UPEC urinary growth and SCN activity were measured essentially as
described (14). Urine samples were supplemented with either 1.5 µM SCN or equivalent volume
PBS. Urines were inoculated in triplicate with UTI89 or isogenic siderophore mutants in 96-well
microtiter plates at 103 CFU/mL and incubated on a platform shaker at 37°C for 20 hours, at
which point each well was serially diluted in PBS and plated on LB agar for CFU enumeration.
For defined media controls, serum-free RPMI 1640 (Gibco, Thermo Fisher Scientific) was
inoculated and growth measured identically as described above. As controls, enterobactin and
iron were added to restrictive urine samples. Iron-free enterobactin was HPLC-purified from
UTI89ΔiroA/ΔybtS-conditioned M63 minimal media supernatant, quantified by UV-Vis
spectroscopy (ε319 = 11,200) (19), and added to urine to 15 µM. Ferric chloride (Sigma) was
prepared in millipore-grade H2O, filter sterilized, and used to supplement urine by 0.08 µg/mL.
Urine pH was experimentally manipulated using sterile sodium bicarbonate (Sigma) or
hydrochloric acid (Sigma).

Chemical enterobactin inhibition. To block enterobactin biosynthesis in wild-type UPEC, we
used

the

drug

((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-

yl)methyl (2,3-dihydroxybenzoyl)sulfamate, or 2,3-DHB-AMS, as described (20, 21). DMSOsolubilized 2,3-DHB-AMS was diluted in sterile millipore-grade H2O before adding to urine
samples at 100 µM. UPEC growth assays were then carried out as described above.

Urine metabolomic analysis. Urinary LC-MS metabolomic profiles were generated as published
(22, 23). Briefly, filtered urine samples were diluted 1:1 with HPLC-grade H2O and analyzed.
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Data was collected on a Shimadzu Prominence UFLC-coupled AB Sciex 4000 QTRAP mass
spectrometer. Separation was carried out on a gradient of 0.1% formic acid (Fluka, Sigma) to
90% acetonitrile (EMD Millipore) + 0.1% formic acid, using an Ascentis Express phenyl-hexyl
column (100 x 2.1 mm, 2.7 µm; Supelco, Sigma). Samples were analyzed by negative
electrospray ionization (ESI) over a mass range of m/z 50 to 1000. Each sample was analyzed in
triplicate, and the entire run order randomized. A quality control (QC) sample, prepared by
mixing an equal volume of each urine sample, was used to pre-condition the column and injected
every ten samples as a measure of stability, confirmed by sample-centered clustering in PCA
analysis (22, 23).

For neutral loss analysis, we selected for ions with an 80 a.m.u. neutral loss fragment to
selectively monitor urinary sulfated aryl alcohols. Using a collision energy range of -20 to -60 V,
we set Q1 to scan from m/z 100 to 1200 while Q3 simultaneously scanned at 80 m/z units less
than Q1. Peaks highlighted for predictive models were then analyzed by enhanced resolution
mode over ~30 m/z windows to confirm the precursor ion mass, and by collision induced
dissociation fragmentation to confirm presence of the prominent [M-H-80]- fragment.

MarkerView v1.2.0 was used for peak alignment, resulting in a data matrix of 600 analyte ion
features. Averaged triplicate runs were Pareto scaled, and unsupervised and discriminate
principal components analyses (PCA and PCA-DA, respectively) were performed with the same
software. Candidate ions were highlighted by the PCA-DA loading plots and by t-tests
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comparing the identified restrictive and permissive sample sets, and were visually verified in the
mass spectra.

Metabolite identification. To identify urinary metabolites we extracted urine using ENVI-Chrom
P SPE (Supelco, Sigma) and eluted with methanol. Further fractionation was achieved by UFLC
chromatography on a Shimadzu Prominence UFLC with a gradient of 0.1% formic acid to 90%
acetonitrile + 0.1% formic acid equipped with an Ascentis Express phenyl-hexyl column (100 x
4.6 mm, 2.7 µm; Supelco, Sigma); then, candidate-containing fractions as determined by LCMS/MS were further purified over a Kinetex C18 column (Phenomenex, Torrance, CA). These
fractions were analyzed on an Agilent 6550 LC-QTOF mass spectrometer to determine
molecular formula. Instrument software (MassHunter B.06.00) matched the spectrum and
calculated isotope distribution to the molecular formula. MS/MS spectra were used to make
preliminary identifications from among the list of isobaric molecules identified by HR-MS.
Preliminary identifications were compared to published urinary profiles and metabolome
database entries for further confirmation (24–28).

Arylsulfatase digestion and gas chromatography-mass spectrometry. Human urine samples were
fractionated by ENVI-Chrom P SPE, reconstituted in water, and analyzed by LC-MS/MS.
Arylsulfatase (Sigma) or buffer control was added at 100 U/mL urine and incubated at 37°C for
4 hours prior to MS analysis. For GC-MS, MSTFA-derivatized samples were analyzed on an
Agilent 7890A gas chromatograph interfaced to an Agilent 5975C mass spectrometer operated in
the electron ionization (EI) mode; the source temperature, electron energy and emission current
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were 230°C, 70eV and 300µA, respectively. GC chromatography was performed with an HP5MS column (30 m, 0.25mm i.d., 0.25µm film coating; P.J. Cobert, St. Louis, MO) with a linear
temperature gradient of 80-300°C at 10°C per minute; the injector and transfer line temperatures
were 250°C. Peaks of interest were matched to the NIST11 Mass Spectral Library for chemical
identification.

Quantitative LC-MS. Relative concentrations of specific sulfated urinary metabolites were
measured by comparing their 80 mass unit neutral loss LC-MS/MS peak areas to that of a 4flourosalicylic acid (4FSA, Sigma; final concentration 5 µM) internal standard. Urines were
combined 1:1 with 10 µM 4FSA prior to analysis. The 4FSA peak was detected using the
MS/MS transition 155>111. Triplicate analyses were performed with samples in randomized run
order. Peaks were normalized and retention time corrected relative to 4FSA in Markerview
before averaging replicate data. Processed peak areas were then normalized to the overall urinary
solute concentration by adjusting to specific gravity as established (29), yielding relative urinary
concentration in arbitrary units. Molecular features distinguishing restrictive and permissive
urines were highlighted by PCA-DA loadings plot and t-test comparison between the groups.
Peaks were confirmed by visual inspection of primary data.

Statistical analysis. Data were tested for significance at α = 0.05 using Prism v. 6.0d (GraphPad).
We used t-test for parametric, and Mann-Whitney U test for non-parametric comparisons, and
one-way ANOVA for multi-group comparisons. Wilcoxon matched pairs sign rank test was used
for non-parametric paired comparisons. Holm-Šídák or Dunn’s tests were used to correct for
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multiple comparisons where appropriate. Logistic regression and receiver operating
characteristic (ROC) analyses were performed in SigmaPlot v. 12.3 (Systat Software, San Jose,
CA).
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RESULTS
SCN markedly inhibits growth of enterobactin-deficient UPEC in pooled human urine. Urinary
SCN concentrations are elevated during E. coli urinary tract infections (Fig. 1), consistent with
several recent studies (30, 31). Even higher local concentrations of this cationic protein (pI ~9)
are likely in the bladder surface’s anionic glycosaminoglycan layer. To determine whether SCN
inhibits UPEC growth, we compared growth of the model E. coli cystitis (bladder infection)
strain UTI89 (103 CFU/mL inoculum) and its siderophore-deficient mutants (2) (Fig. 2a) with
and without purified human SCN. In a chemically defined and iron-poor medium (RPMI 1640),
SCN limited UTI89 growth as previously described (8, 11, 14), with the greatest inhibitory effect
on the mutant UTI89ΔiroA/ΔybtS (P < 0.01), which expresses enterobactin as its sole
siderophore, and the smallest effect on UTI89ΔentB, which expresses yersiniabactin as its sole
siderophore (Fig. 2b). In contrast, when these strains were grown in filtered and pooled human
urine, SCN significantly (P < 0.001) inhibited the enterobactin-deficient mutant (UTI89ΔentB)
but not the yersiniabactin or salmochelin and yersiniabactin-deficient mutants (UTI89ΔybtE and
UTI89ΔiroA/ΔybtS, respectively) when compared to wild type UTI89 (Fig. 2b). Similar results
were obtained with purified mouse SCN (data not shown). These results show that the urinary
growth condition substantially alters the previously described relationship between SCN and E.
coli siderophore biosynthesis. A similar growth discrepancy was previously noted for an
enterobactin-deficient Klebsiella pneumoniae mutant (14). While the RPMI growth results are
consistent with SCN’s previously demonstrated ability to bind ferric enterobactin and deny its
availability to E. coli, the urinary growth results suggest that urinary constituents play additional,
determinative roles in SCN-mediated antibacterial activity.
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Individual differences control SCN antibacterial activity. Urine is a remarkably complex and
variable biofluid whose chemical composition is shaped by multiple idiosyncratic sources
including host metabolism and the intestinal microbiome (26, 32). It is notable that SCN activity
against UTI89ΔentB varied widely between pooled urine sets from different donor groups (larger
error in Fig. 2b). To determine whether this variation originated from individual differences in
urine composition, we compared urinary SCN inhibitory activity between 50 adult healthy donor
specimens (52 percent female; average age 38, range 21 – 76). We inoculated each urine
specimen with UTI89, UTI89ΔentB, or UTI89ΔiroA/ΔybtS and determined SCN’s effect on
growth (Fig. 2c). In aggregate, SCN significantly (P < 0.0001) inhibited growth of each strain;
SCN inhibited UTI89ΔentB substantially more than wild type or UTI89ΔiroA/ybtS (Fig. 2c).
These results again show that disrupting biosynthesis of enterobactin, but not salmochelin and
yersiniabactin, greatly increases SCN’s urinary antibacterial activity.

SCN-mediated growth restriction exhibited the greatest inter-individual variation with
UTI89ΔentB, spanning over eight orders of magnitude, with 42% of samples exhibiting 10-fold
or greater inhibition. To facilitate further between-individual investigations, we classified
individual urines by their entB-dependent SCN activity as in Equation 1 (Fig. 2d).

SCN activity = log10 [WT+SCN growth / ΔentB+SCN growth]
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(Equation 1)

When SCN activity values are displayed for each urine specimen, the wide range of individual
variation is readily apparent. Within this distribution, a threshold is evident where SCN inhibits
UTI89ΔentB 10-fold (SCN activity = 1) more than wild type UTI89. Urine specimens with SCN
activity >1 we therefore defined as restrictive (SCN restricts growth in the absence of
enterobactin) while those with SCN activity <1 are defined as permissive (no SCN-mediated
growth restriction).

To determine whether the differences between restrictive and permissive urines are evident at
earlier bacterial growth time points, we measured viable bacterial counts six hours after
inoculation (Fig. 3). At this time point, restrictive urines (Fig. 3a) exhibited significant SCN
activity against both wild type UTI89 and UTI89ΔentB (Fig. 3b-d), while permissive urines
again exhibited little or no SCN activity (Fig. 3e-g). SCN activity against wild type UTI89 may
reflect insufficient enterobactin accumulation to overcome SCN at this early time point. This
suggests that restrictive urine may inhibit wild type uropathogen growth in vivo at low cell
density.

Purified enterobactin or iron diminishes SCN antibacterial activity. To determine whether the
ΔentB mutant phenotype in restrictive urine derives from deficient enterobactin-mediated iron
import, we chemically complemented UTI89ΔentB urinary cultures with exogenous apoenterobactin or ferric chloride. In three representative restrictive specimens, enterobactin
addition (15 µM final concentration) restored growth to wild-type levels (Fig. 4a). Ferric
chloride addition (0.08 µg/mL) similarly restored growth (Fig. 4b). These results are consistent
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with an important role for classic enterobactin-mediated iron acquisition in SCN-supplemented,
restrictive urines.

SCN antibacterial activity requires an intact calyx. SCN binds ferric complexes with high
affinity through electrostatic and cation-π interactions in its positively charged binding site, or
calyx (11–13). Two lysine residues (K125, K134) and one arginine (R81) contribute local
positive charges that facilitate ferric complex binding. To confirm that SCN’s inhibitory activity
is attributable to calyx binding, we compared urinary growth inhibitory activity between wild
type SCN and a calyx mutant in which the two lysine residues have been mutated to alanines
(SCN K125A/K134A), disrupting the binding site’s shape and positive charge (12). Unlike the
wild type protein, the K125A/K134A mutant failed to restrict bacterial growth in restrictive
urines (Fig. 4b). These results demonstrate that an intact SCN calyx is necessary for SCNmediated urinary growth inhibition.

An enterobactin biosynthesis inhibitor increases SCN antimicrobial activity in urine. To further
discern the enterobactin biosynthetic pathway’s contribution to SCN resistance, we used the
EntE inhibitor 2,3-DHB-AMS as a chemical probe to inhibit enterobactin biosynthesis (20) (Fig.
6a). Compared to SCN or 2,3-DHB-AMS alone, the SCN + 2,3-DHB-AMS combination
markedly inhibited (P < 0.001) UTI89 growth in restrictive urine (Fig. 5b). SCN + 2,3-DHBAMS similarly inhibited growth (P < 0.001) of the genetically distinct pyelonephritis strains
CFT073 and USB64 (33–35) (Fig. 5b). These data are consistent with a role for enterobactin
biosynthesis in resisting SCN-mediated growth inhibition in urine.
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SCN antibacterial activity is associated with urinary pH. To determine whether donor
demographics or basic measures of urine composition are related to SCN activity, we compared
their values in restrictive and permissive subgroups (Fig. 6a). We hypothesized that urine
osmolarity, pH, endogenous SCN, and variations in total metal content could be possible
restrictive correlates (36, 37). Neither age (Fig. 6a) nor individual gender (P = 0.39, Fisher’s
exact test) was significantly associated with restrictive or permissive designation. Among the
chemical analyses, only urine pH, but not endogenous SCN, specific gravity, or metal content
(determined by ICP-OES), distinguished the subgroups. Specifically, higher pH was significantly
(P < 0.0001) associated with restrictive urines (Fig. 6a) and correlated with higher SCN activity
(P = 0.0005; Fig. 6b). Within the urinary pH range, this trend mirrors the greater ferric complex
binding affinity to SCN and the greater ferric ion binding affinity to enterobactin and other
catecholate ligands observed with increasing pH (12, 38).

We further evaluated the relationship between urinary pH and restrictive urine by constructing a
receiver operating characteristic (ROC) curve using the 50-specimen dataset (Fig. 6c). Urinary
pH emerges as a sensitive and specific marker of the restrictive phenotype, with an area under
the curve (AUC) of 0.86 (P < 0.0001). This relationship was confirmed (AUC of 0.87, P <
0.001) in a set of 37 new specimens from our healthy cohort. Using the pH 6.45 cutoff value
from the initial ROC curve, high urinary pH predicted high SCN activity in this validation set,
with a specificity of 92 percent and sensitivity of 80 percent (P < 0.0001, two-tailed Fisher’s
exact test). This relationship was not absolute, however; we observed urine samples with high
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pH and low SCN activity or low pH and high activity (bottom-right and top-left quadrants of
Figure 5b, respectively), as well as wide-ranging activity variation between samples with similar
pH suggesting that other urinary factors influence SCN activity in urine.

Urinary alkalinization sensitizes E. coli to SCN-mediated growth inhibition. To determine
whether urinary pH plays a causative role in making urine restrictive or permissive, we
experimentally measured SCN activity in urine specimens before and after adjusting pH with
reagent sodium bicarbonate or HCl. Bicarbonate alkalinization within a physiologic range (mean
pH 5.9 ± 0.4 to 7.2 ± 0.3, Fig. 6d), converted all tested specimens to restrictive urines. One
specimen completely inhibited both wild type UTI89 and UTI89ΔentB growth after
alkalinization, and therefore could not be plotted. Conversely, HCl acidification within a
physiologic range (mean pH 6.8 ± 0.4 to 5.7 ± 0.3) decreased SCN activity (Fig. 6e). By
experimentally adjusting pH in voided urine, this approach avoids the possible confounding
impact of pH-related changes in renal excretion of acidic or basic metabolites. Overall, these
results show that increasing urinary pH promotes SCN activity.

SCN antibacterial activity is associated with urinary metabolomic features. To seek urinary SCN
activity correlates beyond pH, we used a previously described LC-MS profiling approach to
compare individual urine specimens (22). Unsupervised principal components analysis of LCMS profiling data (PCA, identifies major sources of variation in the data set) revealed extensive
overlap between restrictive and permissive urines, suggesting that SCN activity is not associated
with the dominant sources of urinary metabolomic variation. Supervised PCA-discriminate
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analysis (PCA-DA, highlights major restrictive/permissive associations; Fig. 7a) identified nine
molecular features that best distinguished restrictive and permissive individuals. After
eliminating uncommon molecular features (present in <10 samples) we selected three (m/z 187,
217, and 528 in negative ion ESI; Fig. 7b) that discriminated restrictive and permissive urines.

We hypothesized that these three urinary metabolites would help identify metabolite classes
associated with SCN activity. Tandem mass analysis (MS/MS) revealed the same prominent 80
a.m.u. neutral loss from all three metabolites (Fig. 7c), corresponding to the SO3 neutral loss
observed with MS/MS of sulfated aromatic alcohols and enols by Yi and colleagues (39).
Accurate mass analysis of the most abundant HPLC-purified metabolite at m/z 187.00728
confirmed that it is a sulfur-containing empiric formula (C7H7SO4-), matching cresol sulfate, a
sulfated aryl alcohol (Fig. 7d). Arylsulfatase treatment abolished the molecule’s LC-MS peak
while generating a new GC-MS peak matching that of a para-cresol standard (Fig. 7e,f),
confirming that the aryl sulfate is p-cresol sulfate. Together, these data link urinary aryl sulfates
to urinary SCN antimicrobial activity.

SCN antibacterial activity is associated with urinary aryl sulfates. To more specifically
investigate the association between urinary aryl sulfates and SCN activity we configured the
mass spectrometer to detect only molecules that undergo the aryl sulfate-specific 80 a.m.u. loss
(Fig. 8a) during negative ion MS/MS fragmentation. This LC-constant neutral loss (LC-CNL)
approach greatly improves sensitivity to aryl sulfates in the chemically complex human urinary
background when compared to the LC-MS profiling approach used above (Fig. 8b). PCA-DA
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analysis of LC-CNL data from 20 specimens resolved restrictive from permissive urines (Fig.
8c), and further, this analysis identified new aryl sulfate ions associated with restrictive or
permissive urines for further study.

SCN antibacterial activity is associated with increased urinary aryl sulfate concentrations. To
determine whether specific aryl sulfates are associated with high SCN antibacterial activity, we
compared relative concentrations of 14 aryl sulfates identified in the above aryl sulfometabolome
analyses. In restrictive (n = 21) versus permissive (n = 29) urine specimens (Table 1), five aryl
sulfate concentrations (m/z 189, 202, 217, 269, and 415 in negative ion ESI) were significantly
(P < 0.05) higher in restrictive urine, while none were significantly lower. ROC curve analysis of
the three most significantly elevated (m/z 202, 269, 415; P < 0.002) supported their ability to
predict the restrictive phenotype (AUC values of 0.72, 0.76, and 0.72 for m/z 202, 269, and 415,
respectively, P < 0.01; Fig. 9a). Arylsulfatase treatment further supported identification of these
three diagnostic molecules as aryl sulfates (Fig. 9b), and the relative urinary concentrations were
also significantly correlated with SCN activity level (P < 0.002; Fig. 9c). These trends were
confirmed in a set of 37 new urine specimens. Together, these data further support a positive
association between urinary aryl sulfates and SCN activity.

Structural analyses of the 14 analytes supported their identification as sulfated aryl alcohols, 11
of which have been previously documented in human urine (Table 1) (24–28, 40). This urinary
metabolite class derives from human sulfate conjugation of phenolic metabolites originating
from human, dietary and/or intestinal microbial sources (28, 32, 40, 41). Catechol-containing
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metabolites are notably prominent among these molecules, and their SCN activity associations
are consistent with SCN calyx binding preferences for ferric-catechol complexes. While the
sulfated forms of these aryl alcohols are unlikely to participate directly in iron sequestration (12),
they may be readily detectable (in negative ion ESI-MS) markers of endogenous SCN ligands
and the metabolic processes that produce them.

Aryl alcohol supplementation increases SCN antimicrobial activity. To determine whether
unconjugated urinary catechols contribute to SCN activity in urine, we measured the effect of
model catecholates on urinary SCN activity. We supplemented ten permissive urine specimens
(urinary pH range 5.53 – 7.40) with physiologically achievable concentrations (15 µM) (25, 42)
of three urinary catechol metabolites found in urine that are also known to chelate iron within
SCN complexes: catechol, pyrogallol, and 3-methylcatechol (12). Catechol supplementation
significantly (P = 0.0039) increased urinary SCN activity in permissive urines (Fig. 9d), with
typical individual variations in effect magnitudes. These results support a model in which
elevated aryl alcohol concentrations in restrictive urine directly potentiate SCN’s urinary
antimicrobial activity.

Urinary pH and aryl sulfates are independently associated with SCN antibacterial activity. To
determine whether the urinary aryl sulfometabolome and pH are independently associated with
restrictive urines, we conducted a multivariate logistic analysis. Urinary aryl sulfates were
expressed as the PCA-DA score derived from LC-MS/MS data of the 14 urinary aryl sulfates.
Multiple logistic regression analysis of the complete 87-specimen dataset showed that both urine
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pH (P < 0.001) and LC-MS/MS-derived aryl sulfometabolite DA score (P = 0.002) are
independently and significantly correlated with SCN activity (odds ratio of 48.62 and 2.11,
respectively; Fig. 10a).

Independent contributions of pH and aryl sulfometabolites to SCN activity are visually evident in
a bubble plot of log DA score vs. pH (Fig. 10b) (43). Here, the bubble radius is defined by SCN
activity, and clearly shows both the individual differences in these parameters and the strong
associations between pH, aryl sulfates, and SCN activity. Notably, only a single urine specimen
(1/37, 3%) with borderline low pH and low DA values is restrictive while nearly all (16/18, 89%)
of those with high pH and high DA values are restrictive. A heat map in which urines are
arranged by SCN activity (Fig. 10c) reveals that the highest DA scores (>log 3) are observed in
urines with the highest SCN activity; this is supported by logistic regression analysis, where the
DA score odds ratio is higher, while the pH odds ratio is lower (Fig. 10a). These results show
that urinary aryl sulfates are most highly associated with urines supporting the highest SCN
antibacterial activity levels.

To experimentally determine whether combined pH and aryl alcohol treatment facilitates SCN
activity, we monitored bacterial growth in SCN-treated permissive urines from ten individuals
following combined ex vivo aryl alcohol (as in Figure 9d) and bicarbonate supplementation (as in
Figure 6d, 5 mg/mL as sodium salt). SCN significantly inhibited growth of both wild type (P <
0.001, Fig. 10d) and enterobactin-deficient UTI89 (P < 0.0001, Fig. 10e) in the presence, but not
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absence, of combined aryl alcohol and bicarbonate treatment. These results are consistent with a
critical role for both pH and aryl alcohols upon SCN’s urinary antimicrobial activity.
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DISCUSSION
Together, these results describe a biochemical network in which siderocalin, urinary aryl
metabolites, and enterobactin interact to control bacterial growth. Our conclusion that SCN uses
a subset of urinary metabolites as cofactors to withhold iron from E. coli emerges from an
experimental strategy that used individual human differences as an independent variable; this
approach informed further analyses that identified urinary pH and aryl metabolite associations
with SCN activity. Consistent with these associations are the known pH and catechol
requirements for ferric ion binding by SCN (12). While enterobactin’s role in resisting
siderocalin-mediated growth inhibition in urine was unexpected, it is consistent with the concept
that niche-specific roles drive siderophore diversity among bacterial pathogens (6, 44–47).
Therefore, while enterobactin may be particularly consequential in the urinary environment
examined here, SCN evasion by non-enterobactin “stealth siderophores” may dominate in nonurinary environments lacking urine’s unique aryl metabolite composition.

SCN’s documented ability to form a highly stable complex with ferric enterobactin led us to
initially hypothesize that salmochelin and/or yersiniabactin biosynthesis would be necessary for
growth. Our contrary observations in urine can be explained by the presence of one or more nonenterobactin urinary ligands within the SCN calyx that function as host-derived cofactors (12,
48). Previous work by Bao and colleagues demonstrated that endogenous urinary ligands,
including aryl alcohols as described here, do form stable ferric complexes with SCN (12). Due to
its insolubility in aqueous environments, “free” iron exists in a labile pool, for which aryl
alcohols are well-suited ligands. Indeed, the higher pH associated with restrictive urine closely
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parallels the trends in ferric complex stability and SCN binding observed for catecholate ligands
(12, 38). Because ferric complexes can form from multiple aryl alcohol chelators (e.g., three
divalent catechol chelators per ferric ion) and multiple members of this class may be present in
human urine, restrictive urines may arise from idiosyncratic combinations of these molecules.
The sulfated aryl metabolites tracked here likely represent readily detectable markers of free aryl
alcohols. Future studies will be necessary to identify which of these contribute to SCN activity.

A proposed model for SCN function in the urinary tract is shown in Figure 11. In this model, the
host responds to UPEC by producing SCN, which (at pH > 6.45) stabilizes ferric complexes of
appropriate urinary metabolites in its calyx (Fig. 11a,b). While SCN can bind enterobactin with
high affinity, this interaction may be greatly impeded when urine-derived ferric complexes
occupy the calyx. In this setting, enterobactin’s remarkable ferric ion affinity may instead enable
it to competitively liberate iron from SCN-bound cofactors (Fig. 11c), thus promoting bacterial
growth. This ability suggests a basis for the ubiquitous expression of enterobactin observed to
date in urinary E. coli isolates. While yersiniabactin can avoid SCN binding, it is also an avid
Cu(II) ligand with lower ferric affinity than enterobactin and so may be less able to liberate iron
from SCN as suggested in Figure 2b (3, 6, 49). Similarly, while loss of salmochelin production
did not affect urinary growth (Fig. 2b), we cannot rule out its potential role in liberating SCNbound iron. Further studies are necessary to determine how ferric enterobactin avoids binding to
the SCN calyx following ferric ion removal, which may be attributable to competitive binding or
slow release of aferric urinary ligands. This working model (Fig. 11) suggests important areas for
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future investigation and opportunities for new virulence-targeting UTI therapeutic approaches
distinct from broad-spectrum antibiotics.

The biochemical network described here raises the possibility that promoting restrictive urinary
characteristics in patients may prevent or treat antibiotic-resistant E. coli UTI without incurring
“collateral damage” on the vaginal or gut microbiome (1, 50). This strategy may benefit from an
enterobactin biosynthesis inhibitor such as DHB-AMS. Urinary alkalinization is readily achieved
through existing interventions such as oral bicarbonate therapy. Although favorable urinary aryl
metabolite profiles are associated with the highest level of SCN activity, future studies will be
required to determine how to therapeutically recapitulate this in susceptible patients. The urinary
aryl sulfates identified here (Table 1) and in prior studies are known to originate from the
combination of diet, gut microbial metabolism, and host liver metabolism.

Individual

differences in these metabolites may thus have multiple origins. Of note, urinary catechols are
associated with consumption of polyphenol-rich foods such as tea, coffee, wine and cranberries
(25, 32, 41, 51), suggesting that dietary strategies may be feasible.

Mass spectrometry-based metabolomic approaches have excellent potential to resolve individual
differences relevant to many disease processes (22, 52, 53). While definitive metabolite
identification using these methods is often a laborious process, we were aided here by a specific
ion fragmentation process (neutral loss of 80 a.m.u.) characteristic of a urinary biochemical class
linked by structure to candidate SCN ligands (12, 39). This “molecular bootstrapping” approach,
in which a molecular lead derived from untargeted profiling is used to inform a second round of
55

class-specific profiling, may aid further metabolomic discovery work in UTI and other disease
processes.
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CHAPTER TWO: FIGURES

FIGURE 1. Urinary SCN concentrations are significantly elevated in women with
uncomplicated E. coli cystitis. Female cystitis patients (cystitis, n = 19) exhibit significantly
higher urinary SCN concentrations than asymptomatic controls (controls, n = 30). Data displayed
as Tukey box plots, where the horizontal line shows the median and the mean is indicated by
“+”. P < 0.0001, Mann-Whitney test.
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FIGURE 2. In human urine, SCN imposes an enterobactin biosynthesis requirement for E.
coli growth. (a) The model UPEC strain UTI89 produces three siderophores derived from
chorismic acid precursors. Isogenic mutants disrupting biosynthesis in each pathway are
indicated in red. (b) In RPMI media, 1.5 µM SCN most effectively inhibits a mutant lacking
non-enterobactin siderophores as previously described. In pooled human urine, 1.5 µM SCN
conversely inhibits only the enterobactin-deficient strain. 20-hour growth was monitored by CFU
in urine specimens following a 103 CFU/mL inoculation, and data are shown as mean ± SD of at
least three separate cultures; ns = not significant, **P < 0.01, ***P < 0.001, one-way ANOVA
compared to WT with multiple comparison correction. (c) Bacterial growth phenotypes exhibit
substantial individual variation among unpooled urine specimens from 50 normal donors. Each
data point represents triplicate measures of an individual urine sample, and a red line indicates
the overall mean. Urine was supplemented with 1.5 µM SCN (filled symbols) or PBS control
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(open symbols). ****P < 0.0001, Wilcoxon matched pairs sign rank test; ##P < 0.01, one-way
ANOVA with multiple comparisons. (d) Individual urine specimens can be defined as
“permissive” or “restrictive” based upon their ability to force an enterobactin biosynthesis
requirement for growth in the presence of SCN.
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FIGURE 3. SCN inhibits wild type E.coli growth in restrictive urine at early time points.
Wild type strain UTI89 or its enterobactin-deficient mutant (ΔentB) was inoculated into
restrictive and permissive urine specimens (a) with PBS control (white bars) or 1.5 µM SCN
(black bars) at 103 CFU/mL and grown at 37°C for 6 hours (b-g). Notably, urines (b), (c), and
(d) are restrictive while (e), (f), and (g) are permissive, as defined in Figure 2d; SCN activities
based upon 20-hour growth are re-plotted in (a). These data (b-g) show that restrictive urine
supports significant SCN-mediated antimicrobial activity against wild-type UPEC at this early
time point. Data shown as mean ± SD for three independent cultures. **P < 0.01, ***P < 0.001,
student’s t-test.
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FIGURE 4. In human urine, the SCN calyx interferes with enterobactin-mediated iron
acquisition by E. coli. (a) Purified enterobactin (15 µM) restores enterobactin biosynthesis
mutant (UTI89ΔentB) growth in three representative SCN-supplemented restrictive urines. (b)
Similarly, ferric iron (0.08 µg/mL FeCl3) supplementation restores UTI89ΔentB growth in the
presence of SCN (1.5 µM). A SCN calyx mutant (SCN K125A/K134A, 1.5 µM) does not inhibit
urinary growth of UTI89ΔentB. Bars show means ± SD of three independent cultures.
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FIGURE 5. An enterobactin biosynthesis inhibitor facilitates SCN activity against a panel
of wild type UPEC isolates. The compound 2,3-DHB-AMS, which inhibits EntE by mimicking
the enterobactin biosynthetic intermediate 2,3-DHB-AMP (a), mimics the enterobactin-deficient
(ΔentB) phenotype in wild type UPEC strains UTI89, CFT073, and USB64. (b) Specifically,
combined SCN (1.5 µM) and 2,3-DHB-AMS (100 µM) treatment significantly inhibits all wild
type UPEC growth in restrictive urine. Bars show means ± SD from three independent cultures.
**P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA compared to DMSO.
0.001, &&&&P < 0.0001, SCN + 2,3-DHB-AMS compared to SCN + DMSO, t-test.
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FIGURE 6. Urinary pH distinguishes restrictive from permissive urine. (a) Age and urine
composition of restrictive and permissive urines from normal volunteers. (b) Urine pH is
associated with SCN activity such that more restrictive urines exhibit higher pH values (P =
0.0005; Spearman correlation). The vertical dotted line in (b) indicates the pH 6.45 threshold for
distinguishing restrictive urine identified by ROC curve analysis of 50 urinary pH values (c). The
area under the curve (AUC) value of 0.86 is statistically significant from the null hypothesis of
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0.5 (diagonal dotted line; P < 0.0001). (d) Permissive urine becomes restrictive following ex vivo
bicarbonate (NaHCO3) alkalinization, consistent with a direct urinary pH effect upon SCN
activity [converting from upper left to lower right quadrants in (b)]. (e) Conversely, restrictive
urine becomes permissive following ex vivo HCl acidification, again consistent with a direct
urinary pH effect upon SCN activity. For (d) and (e), connected data points represent the means
of triplicate cultures on a single donor specimen before and after pH manipulation, the order of
which is indicated by the connecting arrow.
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FIGURE 7. Urinary metabolomes distinguish restrictive from permissive urine. (a)
Restrictive and permissive urine samples were analyzed in triplicate by negative ESI LC-MS for
principal components-discriminant analysis (PCA-DA). The discriminant analysis (DA) score is
the supervised principal component distinguishing restrictive and permissive groups in PCA-DA.
(b) Tukey box plots of three metabolites (m/z 187, 217, and 528) that contribute to the DA score
in restrictive (red) and permissive (blue) specimens. (c) MS/MS spectra of these three
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metabolites are dominated by 80 a.m.u. neutral losses. (d) High resolution mass spectra of the
abundant m/z 187 ion matches the exact mass and isotope pattern of cresol sulfate ([M-H]- =
C7H7SO4-). (e-f) Arylsulfatase digestion of this purified metabolite produces a new GC-MS peak
matching that of p-cresol (but not m-cresol) by retention time (e) and EI mass spectrum (f).

67

FIGURE 8. Urinary aryl sulfometabolites distinguish restrictive from permissive urine. (a)
Different sulfated aryl alcohols fragment to lose a common 80 a.m.u. neutral loss in negative ion
ESI MS/MS. (b) Scanning constant neutral loss (-80 a.m.u.) mass spectrum (LC-CNL, retention
time 1-13 min) from a representative urine sample reveals a complex sulfometabolome profile.
(c) Twenty randomly selected (constrained to 10 male, 10 female) urine specimens were reanalyzed by LC-CNL to compare urinary aryl sulfate content in restrictive vs. permissive urines
by PCA-DA. The resulting neutral loss sulfometabolome DA score is the first supervised
principal component distinguishing restrictive and permissive groups in PCA-DA.
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FIGURE 9. Urinary aryl metabolites increase SCN antimicrobial activity. (a) ROC curve
analysis indicates the correlation and predictive capacity for the three most predictive aryl sulfate
ions, measured quantitatively by LC-MS/MS. (b) Arylsulfatase addition reduces LC-MS/MS
signal for each metabolite, further supporting the classification of these molecules as aryl
sulfates. (c) Concentrations of these three metabolites are significantly correlated with SCN
activity (Pearson correlation), and show particular association with high level UPEC growth
restriction (SCN activity >log 3 on y-axis). (d) Ex vivo aryl alcohol supplementation (catechol,
pyrogallol, 3-methylcatechol; 15 µM each) to permissive urines significantly increases SCN
activity. Supplemented (+) and unsupplemented (-) permissive urines (+) was tested for growth
inhibition by 1.5 µM SCN, as before. Points represent experiments from three independent
cultures. **P = 0.0039, Wilcoxon signed rank test.
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FIGURE 10. Urinary pH and aryl sulfates are independently associated with restrictive
urines. (a) Multiple logistic regression analysis of SCN activity shows significant (P < 0.005),
independent associations between SCN activity and pH or sulfometabolite composition. (b)
Bubble plot of all 87 urine specimens tested in this study as a function of pH and aryl
sulfometabolite DA score, where the radius of the bubble equals the SCN activity of the
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specimen. ROC curve-derived cutoffs are indicated by lines. All but one urine specimen with
low pH and LC-MS/MS sulfometabolite DA score are permissive, and the lone exception
possesses a borderline pH value (pH 6.43). (c) Heat map of pH and LC-MS/MS sulfometabolite
DA score ordered by urinary SCN activity level. SCN activity is plotted as bars on the left for
each specimen. Urine pH for each specimen is plotted in heat map from dark blue (lowest value)
to red (highest value; see scale). The rightmost column displays the log LC-MS/MS
sulfometabolite DA score; coloring is the same as for urine pH. The association between highly
restrictive urine (>log 3 SCN activity, “highly restrictive”) and high sulfometabolite DA score is
visually apparent (c) and supported by logistic regression using this elevated activity threshold
(a). Urinary alkalinization combined with aryl alcohol supplementation significantly potentiates
SCN antimicrobial activity against wild type UTI89 (d) and enterobactin-deficient UTI89ΔentB
(e). Ten permissive urines were supplemented as in Figure 9d and alkalinized with 5 mg/mL
sodium bicarbonate, then tested for growth in the presence of 1.5 µM SCN as before. Points
represent experiments on single donor urines from three independent cultures; a horizontal line
indicates the geometric mean ± 95% C.I. ns = not significant, *P < 0.05, ***P < 0.001, ****P <
0.0001; paired, nonparametric Friedman test with multiple comparisons.
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FIGURE 11. Proposed model of SCN antimicrobial activity in restrictive urine. (a) Human
urine contains a complex and variable mixture of metabolites, including aryl metabolites such as
catecholates. Iron is limiting, and exists as a labile pool of low-affinity complexes with numerous
ligands. (b) When UPEC enters the bladder, SCN is upregulated and secreted into the bladder
lumen. Elevated pH facilitates host-derived ferric-aryl complex assembly in the SCN calyx,
starving UPEC of iron. (c) In this context, the siderophore enterobactin is able to outcompete the
SCN-bound complexes for iron, making it bioavailable to UPEC.
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CHAPTER TWO: TABLES
TABLE 1. Aryl sulfate associations with restrictive urine.

m/z
feature

fold higher in
restrictivea

P-value

exact mass
[M-H]-

atomic formula
[M-H]-

preliminary identificationb

ref.

187
189
202
203
205
212
216
217
219
232
269
274
415
528

0.93
1.96
4.30
0.86
1.51
0.67
2.13
2.66
1.75
1.05
5.46
0.98
4.25
1.43

0.7899
0.0176
0.0009
0.7170
0.3515
0.2840
0.1559
0.0182
0.1393
0.7966
0.0004
0.9647
0.0018
0.3033

187.0073
188.9867
202.0185
203.0036
204.9827
212.0038
216.0342
217.0181
218.9986
232.0298
269.0139
274.0046
415.0372
528.2649

[C7H7O4S][C6H5O5S][C7H8NO4S][C7H7O5S][C6H5O6S][C8H6NO4S][C8H10NO4S][C8H9O5S][C7H7O6S][C8H10NO5S][C11H9O6S][C9H8NO7S][C16H15O11S]--c

p-cresol sulfate
catechol sulfate
amino cresol sulfate
methylcatechol sulfate
trihydroxybenzene sulfate
indoxyl sulfate
tyramine sulfate
ethylcatechol sulfate
O-methyl pyrogallol sulfate
dopamine sulfate
--CQAL sulfated
--

(24)
(26)
(40)
(25)
(25)
(26)
(26)
(25)
(27)
(26)

a

(28)

Urinary aryl sulfates were selectively quantified by LC-MS/MS and compared between

restrictive and permissive urines. Five metabolites were significantly (P < 0.02) elevated in
restrictive urines. Fold difference presented as restrictive vs. permissive concentration. P-values
determined by student’s t-test.
b

Preliminary identifications were determined by considering exact mass and atomic formulae,

MS/MS spectra, and reference to published urinary metabolites. Dashes indicate features that
could not be identified with sufficient confidence due to degeneracy of the atomic formula
results or inconclusive MS/MS spectra.
c

Atomic formula could not be determined with sufficient confidence from the exact mass.

d

CQAL = caffeoylquinic acid lactone
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CHAPTER THREE

The innate immune protein siderocalin binds urinary
metabolites to deprive bacteria of iron
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ABSTRACT
During urinary tract infections (UTIs) uropathogenic Escherichia coli (UPEC), the bacterial
pathogen associated with most UTIs, must acquire iron to grow in the micronutrient-limited
bladder environment. Host cells secrete the innate immune protein siderocalin, which
accumulates in the urine and further restricts UPEC iron access by binding ferric complexes.
Recent evidence suggests that urinary composition plays an important role in determining SCN’s
efficacy. The association between SCN antimicrobial activity and small diet-derived aryl
alcohols, some of which are proposed SCN ligands, strongly suggests that urinary ferric complex
formation and sequestration by SCN contributes to its antimicrobial mechanism in urine. Here,
we screened fractionated urine for SCN ligands using a multistep fractionation and validation
assay. Biophysical interactions were validated for several small catecholate metabolites that were
found to be elevated in urines supporting SCN antimicrobial activity. These ligands were then
shown to promote SCN’s antimicrobial activity in defined media conditions, demonstrating that
they indeed are the urinary components that synergize with SCN to restrict UPEC growth.
Lastly, we used native mass spectrometry to highlight the existence of heterogeneous ferricligand complexes within the SCN calyx. Together, these results illuminate how dietary factors
interact with the innate immune protein SCN to fight infections in urine. These findings further
describe how urinary compositional manipulations could aid in controlling UTI susceptibility
and reduce dependencies on traditional antibiotics.
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INTRODUCTION
Urinary tract infections (UTIs) are one of the most commonly experienced bacterial infections
worldwide. Uncomplicated UTIs are most commonly associated with uropathogenic Escherichia
coli (UPEC) colonization, and have historically been treated using common antibiotics (1, 2).
However, rapid emergence and spread of antibiotic resistance in UPEC combined with a paucity
of novel therapies necessitates exploring bacterial pathogenesis to identify new approaches to
combat infection (1, 3). Recurrent infections further complicate treatment options for roughly 25
percent of UTI patients, with unexplained differences in individual susceptibilities (2, 4, 5). A
better understanding of pathogenic mechanisms in the human urinary tract may inform
individualized approaches that promote improved clinical outcomes and antibiotic stewardship
(2, 6).

At the host-pathogen interface, one important mechanistic interaction involves the sequestration
and acquisition of iron (7, 8). Iron is an essential micronutrient for nearly all organisms, and the
human host has developed elaborate systems to restrict its availability and starve pathogens
during infection (9). This innate immune barrier forces UPEC to carry specialized pathways in
order to obtain iron. During UTI, UPEC respond to iron limitation by upregulating the
biosynthetic machinery to make siderophores, or small iron-chelating secondary metabolites,
which effectively compete with host iron binding proteins (10–16). Humans, in turn, express and
secrete the siderophore binding protein siderocalin (SCN), which binds small molecule ferric
complexes including some siderophores (17–20).
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We recently investigated SCN’s ability to restrict UPEC growth in human urine and found
dramatic variability between individuals in the extent of antimicrobial activity. SCN’s activity
was iron dependent, and correlated with elevated pH and sulfated aryl metabolites in the urine.
Because this class of sulfated metabolites contains catecholates and other potential ferric
chelators and SCN ligands (20), we hypothesized that SCN’s antimicrobial mechanism in urine
involves sequestering host-derived ferric complexes. This activity could therefore precede
bacterial siderophore accumulation and fend off infection at an early stage.

Here, we aimed to test this hypothesis, employing a biophysical and mass spectrometry-based
screening methodology to discover physiologic SCN ligands directly from human urine that
supported its antimicrobial activity. Through these analyses, we found that urine supporting
greater SCN activity was indeed enriched for several catecholate metabolites that bound SCN in
ferric complexes. These metabolites are of the chemical class identified by correlation
previously, and derive largely from host and microbiome metabolism of plant-based dietary
precursors (19, 21). These ferric cofactors were able to promote SCN’s activity in defined, ironlimiting media, thus reconstituting the urinary mechanism in a simplified background. Finally,
we suggest that the in vivo context and true SCN calyx occupancy may be overwhelmingly
combinatorial, supporting heterogeneous assemblies of metabolites as preferred ligands.
Together, these results describe the mechanism behind SCN’s antimicrobial activity in human
urine, and provide a blueprint for a urine composition refractory to UPEC colonization.
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EXPERIMENTAL PROCEDURES
Protein purification. Human SCN protein (the kind gift of Roland Strong) was expressed on a
pGEX4T vector in BL21 E. coli as previously described (17, 19). The human SCN calyx mutant
K125A/K134A was expressed on a pET22b vector in BL21 E. coli and purified as described (19,
20). Protein purity was monitored by mass spectrometry and SDS-PAGE.

Media growth assay. Defined media used to test metabolite supplementation were M63 minimal
salts media supplemented with 0.2% glycerol and 10 µg/mL niacin, and serum-free RPMI
(Gibco). SCN activity assays were performed essentially as described (19, 22). Briefly, media
was inoculated with the uncomplicated cystitis isolate UTI89 or isogenic siderophore mutants
(12) at 103 cfu/mL, from 4-6 hour cultures in LB broth. Cultures were grown with 1.5 µM SCN
or an equivalent volume of PBS. After 20 hours, viable bacterial concentrations were determined
by cfu enumeration. Where indicated, media was supplemented with candidate metabolites at 5
µM.

Urine fractionation. Healthy donor urines were collected as approved by the Washington
University School of Medicine Institutional Review Board, and described previously (19). To
fractionate and concentrate urinary small molecules, we used a multi-step chromatographic
scheme. Four urines of either high or low SCN antimicrobial activity were pooled (2 mL each)
and applied to Chrom P SPE cartridges (Supelco). The flow through, water wash, and elutions
with 50% and then 100% HPLC-grade methanol (Sigma) were all collected and lyophilized to
dryness. Each of the four preparations was then rehydrated in HPLC-grade water (Sigma) and
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fractionated over a phenyl-hexyl Eternity column (250 x 4.6 mm, 5 µm; Supelco) using a
water:methanol gradient on a BioLogic DuoFlow chromatography system (Bio-Rad). All
fractions (~290 total) were lyophilized to dryness and stored at -80°C until analysis.

Differential scanning fluorimetry. To screen for SCN binding in urinary fractions, we measured
thermal denaturation through differential scanning fluorimetry (DSF), essentially as described
(23). Lyophilized urinary HPLC fractions were reconstituted in 100 µL HPLC-grade water thus
yielding a roughly 80-fold concentration from the original bulk urine. Fractions (10 µL) were
added to a final concentration of 3 µM SCN in PBS with a 5X concentration of SYPRO Orange
dye (Sigma), and allowed to equilibrate for 20 minutes. Using a CFX96 real-time PCR machine
(Bio Rad), reactions were then heated in 96-well quantitative PCR plates (Bio Rad) from 22°C to
98°C at 1°C per minute, with plate reading at each increment. Melt transitions were monitored
on the HEX channel and displayed as the derivative of relative fluorescence units with respect to
temperature (dRFU/dT). Fractions were also analyzed in the absence of protein as a negative
control, and SCN was incubated with ferric catechol (30µM) as a positive control, and negative
controls included protein plus iron and fractions without protein present. Interesting fractions
were identified by a melting temperature (TM) shift.

Preliminary compounds identified by GC-MS were also confirmed by DSF. These reactions
were carried out as above, but with a ferric complex (FeL3) concentration of 30 µM. Chemicals
were purchased from Sigma Aldrich and prepared with FeCl3 or without (equal volume PBS) at a
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1:3 ratio of iron to ligand (i.e. FeL3). SCN melt curves were performed as above, and a positive
DSF result was considered a TM shift or loss of the melt signal.

Fluorescence quenching. We confirmed metabolite-SCN interactions by measuring binding of
DSF-positive candidates by intrinsic tryptophan fluorescence quenching, essentially as described
(17, 20). SCN protein (500 nM) was mixed with a dilution series of ligand in the presence and
absence of iron in PBS with 2% DMSO in black 96-well fluorescence plates (Corning). After
one-hour equilibration, tryptophan fluorescence was monitored at excitation and emission
wavelengths of 281 nm and 340 nm, respectively, on a TECAN M200 plate reader at room
temperature. Binding was monitored up to 48 hours later with no loss of signal or notable change
in fluorescence quenching patterns (data not shown).

Gas chromatography-mass spectrometry. Fractions identified by DSF as containing SCNbinding character were profiled by gas chromatography-mass spectrometry (GC-MS). Briefly,
MSTFA-derivatized samples were analyzed on an Agilent 7890A gas chromatograph interfaced
to an Agilent 5975C mass spectrometer operated in the electron ionization (EI) mode; the source
temperature, electron energy and emission current were 230°C, 70eV and 300µA, respectively.
GC chromatography was performed with an HP-5MS column (30 m, 0.25mm i.d., 0.25µm film
coating; P.J. Cobert, St. Louis, MO) with a linear temperature gradient of 80-300°C at 10°C per
minute; the injector and transfer line temperatures were 250°C. Fraction spectra were matched to
the NIST11 Mass Spectral Library for chemical identification using AMDIS, and metabolites
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elevated in binding fractions compared to non-binding fractions were identified as potential
ligand candidates and analyzed further by DSF and FQ.

To quantify SCN-binding metabolites by GC-MS, we produced calibration curves for each
metabolite relative to the exometabolite 4-fluorosalicylic acid (4FSA) (19). Several metabolites
could not be quantified because no standard was available, or the standard was not reliably
detectable by GC-MS. Urine specimens (100 µL) were spiked with 200 picomoles of 4FSA and
treated with 2.4 units of urease (Sigma) for 40 minutes before quenching with 1 volume of
methanol. The reaction was dried under nitrogen and derivatized as described above. GC-MS
was performed in SIM mode based on the two fragment ions for each candidate that were used
for standard curves. Both fragment ions were monitored to assure correct identification. Molar
concentrations were determined using the standard curve slope to correct the integrated peak area
ratio of 4FSA and the analytes of interest.

Native mass spectrometry. SCN protein (30 µM) was prepared in 50 mM ammonium acetate
(Sigma), pH 6.95. Where indicated, FeCl3 (50 µM) and ligand compounds (60 µM for individual
compounds; 100 µM for mixed compounds) were added, equilibrated at room temperature for 2
hours, then stored at 4°C until analysis. A 10 µL sample was loaded into a nanoES spray
capillary (Thermo Scientific) for native electrospray ionization and mass spectra were acquired
with a Bruker Solarix 12T FTICR mass spectrometer (Bruker Daltonics, Bremen, Germany). The
capillary voltage was 0.9-1.3 kV. The drying gas temperature was 30°C; its flow was 1 L/min.
The voltage for ISCID was set at 70 V to help desolvation. The ion-funnel RF amplitude was 300
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Vpp, and the ion-funnel voltages were 200 V (funnel 1) and 18 V (funnel 2). RF frequencies
used in all ion-transmission regions were the lowest available value: multipole 1 (2 MHz),
quadrupole (1.4 MHz) and transfer line (1 MHz). The collision voltage for the collision cell
varied from 0 to 50 V. Ions were accumulated for 500 ms in the RF-hexapole ion trap before
being transmitted to the infinity ICR trap. The time-of-flight was 1.3 ms for the protein-ligand
ions. The source region pressure was 2.3 mbar; the quadrupole region pressure was 4.4x10-6
mbar, and the trap-chamber pressure was 1.3x10-9 mbar. The typical ECD pulse length was 0.06
s, with ECD bias 0.6 V and ECD lens 10 V. The ECD hollow cathode heater current was 1.6 A.
MS parameters were slightly modified in each individual sample to obtain an optimized signal.
One to several hundred scans was averaged for each spectrum. External calibration was done by
ESI of cesium perfluoroheptanoic acetate, up to m/z 8500.

Statistical analyses. Data were analyzed in Prism v. 6.0d (GraphPad). For parametric and nonparametric two-sample unpaired comparisons we used t-test and Mann-Whitney U test,
respectively. To compare multiple groups versus control or each other, we used one-way
ANOVA. Where appropriate, post-tests were used to correct for multiple comparisons.
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RESULTS
SCN ligand detection using differential scanning fluorimetry. Our previous work suggested that
urinary constituents control SCN’s antimicrobial activity through interactions with its calyx. To
test the hypothesis that SCN ligands present in urine are causative players in its antimicrobial
activity, we screened restrictive and permissive human urine specimens for SCN binding.
However, human urine is chemically complex and highly variable between individuals;
furthermore, salt concentrations and buffer incompatibilities preclude using many biophysical
binding assays for SCN ligand screening. We therefore exploited ligand effects on protein
thermal stability to screen for binding by differential scanning fluorimetry (DSF). Compared to
many common binding assays, this technique is highly tolerant to variable ligand concentrations
and complex sample matrices, and is amenable to semi-high-throughput screening with low
reagent consumption.

To confirm that DSF is an appropriate assay for SCN binding, we compared binding to between
DSF and intrinsic tryptophan fluorescence quenching (FQ), which has been demonstrated
extensively for this protein (17, 20). Enterobactin exhibited stoichiometric binding to SCN by
FQ, as expected (Fig. 1a) (17). SCN quenching was also achieved by titration with ferric 2,3dihydroxybenzoic acid (2,3-DHBA; Fig. 1b), but this quenching effect was lost in the SCN calyx
mutant (SCN K125A/K134A; Fig. 1d) (20). A non-binding benzoic acid, 2,5-dihydroxybenzoic
acid (2,5-DHBA, or gentisic acid) does not quench SCN fluorescence, as established (Fig. 1c)
(24). These results are recapitulated in DSF as shown in Figures 1e-h. Ferric complex binding
shifted and reduced the melting transition of apo-SCN, as shown for enterobactin and ferric 2,392

DHBA (Fig. 1e,f), effects that were not seen with the negative control 2,5-DHBA (Fig. 1g), or
with SCN K125A/K134A and ferric 2,3-DHBA (Fig. 1h). These results establish DSF as an
effective screening tool for SCN ligand binding.

Urines supporting SCN antimicrobial activity possess SCN-binding chromatographic fractions.
We hypothesized that fractions of human urine would display SCN binding by DSF. To improve
binding assay interpretation and downstream chemical comparisons, we aimed to reduce the
chemical complexity of a single DSF reaction. To accomplish this, we devised a multi-step
chromatographic fractionation protocol (Fig. 2a). We previously divided urine specimens into
two categories based on their level of antimicrobial SCN activity (19). Urines where SCN was
able to restrict growth of the enterobactin-deficient UTI89ΔentB relative to wild type by at least
90% were termed restrictive; urines that supported no measurably SCN activity were called
permissive. In order to compare restrictive and permissive compositions more generally here, we
pooled four restrictive urines and four permissive urines (Table 1), then extracted metabolites
over solid phase ENVI-Chrom-P resin (Fig. 2a). We collected flow-through, water wash, and
elutions with 50% and 100% methanol (v/v). These preparations were each then fractionated
further by HPLC, dried, and reconstituted in water. The reconstituted fractions represented a
roughly 80-fold concentration over the initial urine matrix, assuming minimal loss due to
chromatography or chemical instability.

All 290 reconstituted urine fractions were used in DSF reactions at a 1:4 dilution, in the presence
and absence of 3.2 µg/mL iron (Supplementary Fig. 1). SCN protein was melted and monitored
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as above. Melt transitions were compared to identify fractions yielding a ΔTM representing
possible SCN ligand binding. As would be expected, ΔTM transitions clustered into groups of
several fractions, likely representing both the main area of chromatographic peaks
(Supplementary Fig. 1). Particularly interesting were fractions that showed increased ΔTM values
in response to additional iron; these fractions are highlighted in Figure 2b,c. This response would
be predicted with iron-dependent ligand complex formation in the SCN calyx (20). We detected
these binding signatures in fractions from each SPE elution, suggesting the presence of multiple
chemically distinct ligands. Despite no significant difference in the average specific gravity
(Table 1), the restrictive fractions contained noticeably larger thermal shifts, particularly in the
presence of iron, than the permissive samples (Fig. 2b vs. Fig. 2c). These data represent direct
detection of iron-dependent urinary SCN binding activity from human urine. Our method yielded
fractions with reduced chemical complexity, which enabled both binding assay sensitivity and
the ability to proceed with mass spectrometry-based ligand identification directly from these
same fractions without further purification.

Metabolomic analyses of SCN-binding urinary fractions. We next asked how the composition of
these binding fractions differed from those without evident binding. We hypothesized that the
responsible molecules would be small, aromatic metabolites based on the structure of the SCN
calyx and existing work on potential urinary ligands of SCN (19, 20, 24). Furthermore, previous
work from our laboratory identified markers of aryl alcohol metabolites as correlates of SCN
antimicrobial activity in urine (19). Because of this, we used gas chromatography-mass
spectrometry (GC-MS) to profile the urinary fractions and preliminarily identify candidates
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enriched in binding relative to non-binding fractions. Supplementary Table 1 summarizes the
results of these comparisons. Candidates shown were detected in binding fractions, and the
summed peak heights across the binding fraction were compared between restrictive and
permissive pools. This comparison highlights potential contributions to the observed
antimicrobial activity in restrictive urines. Metabolites enriched in permissive urines are also of
interest for the possibility that they act as decoy ligands that prevent antimicrobial activity.

Among the metabolites preliminarily identified as enriched in restrictive urines are previously
proposed SCN ligands (e.g. pyrogallol and methylcatechol) (20), as well as other novel
catecholates (propyl gallate, 3,4-dihydroxyhydrocinnamic acid, 4-hydroxyhippuric acid) and
non-catecholates (ferulic acid, hydroxyphenylacetic acid) (Supplementary Table 1). Notable also
is the presence of several methylated catecholate, or methoxy, benzoic acid derivatives, which
may arrive from host catechol-O-methyltransferase activity on catecholate species (25, 26).
Despite the reduced chemical complexity in these HPLC fractions, they are still complex
mixtures of metabolites. To validate each candidate’s contribution to the observed SCN thermal
shift, we turned to a binding assay with purified components.

Urinary metabolites exhibit iron-dependent SCN binding. To determine which metabolites in the
DSF-positive fractions truly contribute to SCN binding, we repeated our SCN DSF screen using
pure compounds. In this assay, we included all GC-MS candidates that were commercially
available, as well as the free aryl alcohols of several sulfated metabolites previously associated
with SCN activity by an LC-MS metabolomics strategy (19, 27). Candidate metabolites were
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measured in the presence and absence of iron at a 1:3 ratio to ligand (expressed as FeL3),
consistent with typical iron coordination by catecholates (20, 28). Ligand alone or ligand with
iron was added to 3 µM SCN and melted as described above. Melting temperature shifts or
ablation of the protein melt signature were considered positive results (Fig. 1d,e). In our analysis,
12 of 22 tested metabolites affected SCN melting measured by DSF (Fig. 3). Interestingly, all
DSF-positive candidates contained a di- or tri-hydroxybenzene motif, consistent with Fe(III)
chelation and SCN binding (20, 29).

The loss of a SCN melt transition in the presence of some ligands, including enterobactin (Fig.
1a), was intriguing. While this result could be explained by greatly enhanced stability of the
protein complex, it is also possible the redox-sensitive catecholate ligands disrupted the behavior
of the SYPRO dye. To more directly measure iron-dependent SCN binding, we followed up our
DSF screen with SCN fluorescence quenching on DSF-positive ligands, which relies on SCN’s
intrinsic tryptophan fluorescence, as previously described (Fig. 1a-d) (17, 20). We measured
SCN’s ability to bind DSF-positive candidates using this method in the presence and absence of
iron (Fig. 4). As shown above, the SCN calyx mutant K125A/K134A was unable to bind ferric
complexes in this assay (Fig. 1d). Here, pyrogallol was uniquely capable at binding SCN in the
absence of iron, while several other candidates including pyrogallol exhibited strong irondependent binding (Fig. 4a,b), consistent with the iron effect seen in our original DSF screen.
Ferric complex binding divided these candidates into three categories (Fig. 4a,b): those with little
or no quenching, such as 2-amino-4-methylphenol and t-ferulic acid (black lines); those with
moderate quenching, such as caffeic acid and 4-methyl catechol (blue lines); and those with
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nearly complete quenching at high concentrations, including catechol, pyrogallol, and 3methoxycatechol (red lines). These data confirm both novel and previously proposed metabolites
as SCN ferric ligands, and serve as an orthogonal validation strategy in our physiologic ligand
screen.

Comparing chemical structures within each level of SCN binding (Fig. 4b) revealed intra-group
structural preferences consistent with the calyx topography (20, 24, 29). The greatest binding
signature was detected in small, di- and tri-hydroxybenzenes with aromatic substitutions located
at 1, 2, and 3-carbon positions. Consistent with previous findings, substitutions at the 4-position
were less sterically favorable and indeed, di- and tri-hydroxybenzene metabolites with this
structure produce only moderate quenching (24, 30). Finally, metabolites without di- or trihydroxy moieties and 3,4-dihydroxybenzoic acid derivatives were unable to bind and quench
SCN fluorescence (Fig. 4b). Together, these results used an unbiased binding screen to detect
and validate physiologic SCN ligands from human urine that were enriched in samples
supporting greater antimicrobial activity.

SCN’s ligands potentiate its antibacterial activity. We next sought to recapitulate the urinary
antimicrobial mechanism in a defined system, hypothesizing that if these urinary ligands directly
participate in potentiating SCN’s antimicrobial activity, supplementing a minimal, defined
chemical media with these metabolites could mimic the antimicrobial activity seen in urine. To
test this, we used two defined conditions: the minimal salts media M63, and serum-free RPMI.
While both are iron limiting, RPMI is more chemically rich. We then supplemented these media
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with physiologically relevant concentrations of caffeic acid, catechol, or pyrogallol (5 µM) and
measured 20-hour bacterial growth in the presence and absence of SCN (1.5 µM) (19). In M63,
SCN restricted wild-type UTI89 and the enterobactin-deficient mutant, UTI89ΔentB growth only
when supplemented with ligands (Fig. 5a). In contrast, a non-binding metabolite, t-ferulic acid,
did not synergize with SCN to restrict growth in M63 (Supplementary Fig. 2). This effect was
also evident with lower ligand concentrations, as 1.5 µM pyrogallol significantly (p < 0.05)
restricted UTI89ΔentB growth in combination with 1.5 µM SCN (Supplementary Fig. 3).

In non-supplemented RPMI, SCN restricted wild-type UTI89 growth, but not UTI89ΔentB,
consistent with enterobactin sequestration as demonstrated previously (Fig. 5b) (19, 22, 31).
When supplemented with candidate ligands however, SCN significantly restricted only the entB
mutant (Fig. 5b). A slight growth increase was observed in UTI89 with catechol and pyrogallol,
which may be an effect of improved iron solubility or excess exogenous SCN ligands that
allowed enterobactin to function unperturbed. Overall, distinct SCN effects in M63 and RPMI
are further evidence that growth environment, whether human-derived or chemically-defined,
can have a determinative role when measuring antimicrobial activity. Catecholate
supplementation in rich media (LB), for example, did not potentiate SCN activity against wild
type or enterobactin-deficient UTI89 (Supplementary Fig. 4).

In both media conditions, the ligands’ potentiating effects were most significant against
UTI89ΔentB, where the bacteria lack endogenous enterobactin production (Fig. 5). This is
consistent with our hypothesis from studies on human urine that enterobactin is especially suited
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to liberating iron from SCN-bound ferric complexes (19). Overall, these results demonstrate that
urinary SCN ligands associated with restrictive specimens are sufficient to reconstitute SCN
activity in a simple, defined chemical system.

Urinary ligand concentrations are correlated with antimicrobial activity. To more accurately
correlate SCN ligands’ presence with antimicrobial status, we wanted to determine their absolute
concentrations in human urine specimens. To accomplish this, we developed GC-MS standard
curves relative to an exometabolite standard, 4-fluorosalicylic acid (4FSA). Urine samples were
urease treated and derivatized for GC-MS analysis without any further extraction or
manipulation. Some metabolites of interest could not be quantified by this method due to low
abundance or poor ionization and detection in GC-MS. We successfully measured absolute
concentrations of 5 ligands in human urines (n = 28) for which the SCN activity was previously
tested (19). Pyrogallol, one of the best candidate ligands in our screen and fluorescence assay,
was significantly (p = 0.0007) elevated in the restrictive relative to permissive urines (Fig. 6a).
More specifically, pyrogallol concentrations were significantly (p < 0.0001) correlated with
increasing SCN activity as measured previously (Fig. 6b) (19). Furthermore, free pyrogallol
concentrations measured here were highly correlated (p < 0.0001) with the relative abundance of
its sulfate conjugate, pyrogallol sulfate (m/z 205 in negative ion ESI), identified in our previous
study (Supplementary Fig. 5). This finding supports our previous hypothesis that the aryl sulfate
signatures represent their free aryl alcohols (19).
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While the other metabolites quantified in the urine set showed a consistent tendency toward
higher molar concentrations in restrictive urines, these did not reach statistical significance at this
sample size (Supplementary Fig. 6). However, our previous study showed that the aryl
metabolite contribution was particularly correlated with high SCN activity (> log 3) samples
(19). When we examined the ligand concentrations among highly restrictive urines in this dataset
(n = 7) versus permissive urines (n = 9), the association with restrictive urines improved for
pyrogallol (p = 0.0006), catechol (p = 0.09), and caffeic acid (p = 0.02; Supplementary Fig. 7).

SCN binds heteromeric ligand complexes. The SCN calyx contains three similar, but not
identical, pockets that each bind one of enterobactin’s catecholate rings (17, 32). These sites are
also responsible for binding other ferric catecholate and non-catecholate siderophores and small
molecule ligands, demonstrating the SCN calyx’s versatility and ligand degeneracy (20, 32–34).
Because the urinary ligands and enterobactin fragments exist mostly as single catecholate rings,
we hypothesized that SCN may bind mixtures of these ligands as a single ferric complex; due to
the calyx asymmetry, some mixtures may even be more avid ligands than a single homogeneous
complex. Previous ligand studies using predominantly crystallography and biophysical assays
could not resolve heterogeneous complexes, as the data interpretation relies on population
averages (17, 20, 32). Indeed, our DSF screens may reflect ligand combinations, but those
species are not identifiable by melting or fluorescence. In order to resolve whether SCN can bind
heterogeneous mixtures, we used non-denaturing, or native, mass spectrometry. This technique
uses “soft” ionization coupled with high-resolution mass spectrometry to detect intact non-

100

covalent complexes (35–38). Because each holo-SCN complex has a unique mass, mixed calyx
occupants can be differentiated by their distinct m/z shift from the apo protein.

To determine whether SCN can stably bind mixed complexes, we analyzed SCN by native MS in
the presence of iron and several aryl alcohols. Using FTICR mass spectrometry, apo-SCN
appeared as a sharp peak at m/z 2298.2, matching the [SCN+9H]9+ charge state ion with an
observed mass of 20,674.8 Da (calculated mass from sequence = 20,675 Da; Fig. 7a).
Equilibrating SCN with Fe(III) and ligand compounds resulted in new peaks corresponding to
ferric pyrogallol and caffeic acid dimers but did not show complex formation with salicylic acid,
consistent with biophysical binding data (Supplementary Fig. 8) (24). Interestingly, when
pyrogallol, caffeic acid, and catechol were mixed together with SCN, a single new peak was
evident. This peak had a 356 Da mass shift, closely matching that for a mixed
[Fe(pyrogallol)(caffeic acid)]1- complex.

We then analyzed SCN complexes by nano-electrospray ionization coupled qTOF mass
spectrometry. This native MS platform detected the [SCN+8H]8+ charge state with an observed
deconvoluted mass of 20673.5 ± 3.1 Da, as well as a +60 adduct species (Fig. 7b). SCN was then
equilibrated with the urinary ligand catechol and 2,3-dihydroxybenzoic acid (2,3-DHB), the
catecholate biosynthetic building block of enterobactin (39). Here, nearly all apo-SCN was
converted to mass-shifted complex species (Fig. 7b). We detected a smaller peak that closely
corresponds to [Fe(DHB)(catechol)]1-, and prominent peaks that match the expected shift for
[Fe(DHB)(catechol)2]3- and [Fe(DHB)2(catechol)]3-.
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Together, these results underline SCN’s degenerate binding capacity and highlight the strength
of mass spectrometry in identifying small molecule-protein complexes from samples with
potential mixed species. To our knowledge, this is the first demonstration that SCN binds
heterogeneous ligand complexes.
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DISCUSSION
Together, these results show how human urinary metabolites govern the antimicrobial
mechanism of an important innate immune protein, siderocalin. By starting with human
specimens and developing a sequential fractionation scheme, we were able to reduce the
chemical complexity and employ direct biophysical measurements on physiologically relevant
mixtures. Coupling binding assays with mass spectrometry allowed us to identify multiple SCN
ligands present in human urine, that were correlated with SCN’s previously demonstrated urinary
antimicrobial activity (19, 22). Supplementing defined media with these ligands at relevant
concentrations potentiated SCN activity, thus supporting the mechanistic link between
endogenous SCN ligands and its ability to control UPEC iron acquisition and growth in human
urine.

We hypothesized that aryl alcohol metabolites present in urine might act as key SCN cofactors in
restricting bacterial iron uptake. This chemical class was previously highlighted as putative in
vivo SCN cofactors, first by a crystallographic screen using pure compounds (20), and recently in
a targeted metabolomic study correlating sulfated aryl alcohols and elevated pH with SCN
activity in human urine (19). Our findings presented here are consistent with these reports, and
demonstrate the mechanistic role for aryl metabolites in SCN antimicrobial activity. Several of
the catecholate metabolites, such as pyrogallol, methylcatechol, and catechol, have now been
identified by multiple distinct approaches as relevant SCN cofactors. These ligands are also
known to chelate iron in a pH-sensitive manner that closely marks the elevated pH correlation
with SCN activity (19).
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These SCN-ligand interactions may have applications beyond urinary tract pathogenesis. The
metabolites identified here, along with similar metabolites, are not exclusively found in urine,
but present in tissue and serum as well, where metabolic diversity is increasingly gaining
recognition for its impact on human health (40–42). Since its discovery, SCN has been
implicated in metabolic diseases, cancer, endogenous iron homeostasis, and other non-urinary
infectious diseases (43–49), however its role or mechanism of action in these conditions has
largely remained a mystery. The ligand interactions described here could occur in other host
environments, providing SCN a means of transporting iron, as proposed previously (20), and also
sequestering iron from pathogens that do not rely on siderophores bound by SCN. These
interactions could, for example, help explain SCN’s protective effect against Klebsiella
pneumoniae respiratory infection models, even when the pathogen encodes multiple SCNevading siderophores (22). Further studies including metabolomic manipulations as a
mechanistic variable in inflammatory models will be necessary to determine SCN’s action in
these contexts.

The ligands’ ability to promote SCN’s antimicrobial activity in defined media, as shown here,
also supports the previously proposed role of enterobactin. We previously showed that in urines
with restrictive composition, UPEC required the siderophore enterobactin to acquire iron in the
presence of SCN (19). In both supplemented media conditions, the enterobactin-deficient mutant
UTI89ΔentB was especially susceptible to cofactor-mediated SCN growth restriction.
Enterobactin faces similar pH dependencies as the catecholate ligands, and its superior iron
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affinity may contribute to its protective effect here (20, 50). Ultimately, the fate of SCN
following this confrontation is unclear; it may retain de-ferrated aryl ligands or bind a subset of
the ferric enterobactin pool, and likely exists in some dynamic mixture of these states in vivo,
reflecting constant changes in urine composition, volume, and bacterial presence. Our
biophysical measurements suggest that as pure complexes, these metabolites do not bind with as
high an affinity as enterobactin, consistent with prior literature (Fig. 1a, Fig. 4b) (20). However,
we show for the first time that heterodimeric and heterotrimeric ligand mixtures are possible, and
indeed appear to be preferred SCN ligands in some mixed systems. In the complex urinary
environment with multiple potential ligand species, enterobactin competition is a much more
complex scenario than often played out in vitro. Native MS is demonstrated here as a powerful
complement to traditional biophysical approaches to study small molecule ligand interactions
with proteins, and further studies could apply these techniques to answer questions about in vivo
ligand occupancy.

A causal, mechanistic link between diet-derived metabolites and antimicrobial activity suggests
avenues for non-traditional antibiotic UTI control. Patients suffering from recurrent cystitis could
benefit particularly from controlling urinary composition to limit bacterial colonization. Aryl
metabolites such as pyrogallol, caffeic acid, and catechol derive from many plant-based
polyphenolic precursors, often cited as products of coffee, tea, berry, and wine consumption (21,
51–53). Cranberry products have long been touted for UTI prevention, but recent literature
reviews and carefully controlled studies often fail to find robust, significant benefits (6, 54, 55).
The results presented here suggest that some metabolites present in cranberries, tea, and coffee,
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for example, may indeed potentiate SCN’s protective activity. However, because iron
sequestration requires an alkaline pH and many urinary metabolites may require particular gut
microbiome compositions (19, 40, 42, 56), the beneficial effects may be masked or inconsistent
in existing human studies. Further understanding the effects of these manipulations on SCN’s
antimicrobial activity could inform future clinical interventions designed to reduce UTI
susceptibility.
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CHAPTER THREE: FIGURES

Figure 1. Differential scanning fluorimetry (DSF) detects SCN-ferric complexes. Known
SCN ligands enterobactin (a) and 2,3-dihydroxybenzoic acid (2,3-DHBA) (b) quench SCN’s
(500 nM) intrinsic tryptophan fluorescence, as established. Titration with a benzoic acid that
does not bind SCN (2,5-DHBA) does not exhibit quenching (c), and neither does the SCN calyx
mutant, K125A/K134A (500 nM), which is unable to bind ferric complexes (d). DSF of these
complexes validates this technique’s ability to detect small molecule binding to SCN. SCN (3
µM) binding produced either a notable reduction in thermal melt signal, as observed with 30 µM
ferric enterobactin (e), or an increased melting temperature (TM), such as with 30 µM ferric 2,3DHBA (f). Consistent with the quenching results, the DSF signal is unchanged in the presence of
30 µM ferric 2,5-DHBA (g), and similarly no change is seen when SCN K125A/K134A (3 µM)
is melted in the presence of ferric 2,3-DHBA (30 µM) (h).
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Figure 2. DSF screening reveals multiple iron-dependent SCN-binding fractions in human
urine. (a) Urine fractionation scheme. Four restrictive (red squares) and four permissive (blue
circles) urines were pooled and extracted before HPLC fractionation. To screen for SCN ligands,
HPLC fractions (reconstituted to approximately 80-fold concentration over starting urine) were
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screened both with and without iron by DSF in the presence of iron. Example melt curves from
the 290 fractions are shown in (b) for restrictive and (c) for permissive. DSF identified several
physiologic urine fractions, shown here, producing iron-dependent SCN binding profiles.
Importantly, these effects were more pronounced in the fractions from restrictive specimens than
from permissive, and showed iron-responsive changes in thermal stability.
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Figure 3. Urinary aryl alcohols perturb SCN thermal stability. Candidate metabolites and
known SCN ligands were obtained commercially and tested for SCN binding in the presence and
absence of iron. Compounds were mixed 3:1 with PBS (in blue) or FeCl3 (in red) and added to
SCN (3 µM) before measuring thermal stability by SYPRO Orange fluorescence. Plots are
shown as the first derivative of the fluorescence signal (arbitrary units); black lines show SCN
with buffer alone. Based on the behavior of known ligands (catechol, 3-methylcatechol) TM
shifts or signal ablation were considered positive results to be analyzed further. Of the 22
compounds tested, 10 had no impact on SCN’s DSF signal; 12 showed increased thermal
stability or decreased DSF signal, consistent with protein-ligand interactions. Notably, these
effects were potentiated by iron with several candidates.
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Figure 4. Direct measurement of SCN binding validates urinary ligands. SCN binding was
directly observed using intrinsic tryptophan fluorescence quenching. DSF-positive candidates
were added to SCN (500 nM) at a range of concentrations in the absence (a) or presence (b) of
FeCl3 at a 1:3 molar ratio to the compound. Candidate metabolites cluster into three binding
groups: in black are metabolites that do not bind SCN even at large molar excess; in blue are
intermediate ligands that bind moderately, and most only in the presence of added iron; in red are
preferred ligands that show some binding in the absence of supplemental iron, and show the
highest binding and nearly complete quenching when present in excess as ferric complexes.
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Figure 5. Candidate ligands potentiate SCN’s antimicrobial activity in defined growth
media. (a) In M63 minimal media, supplementation with SCN ligands catechol, pyrogallol, or
caffeic acid (5 µM) limits UPEC growth when combined with 1.5 µM SCN. Treatment with 1.5
µM SCN alone (SCN + water) does not limit UPEC growth in M63. Growth restriction is most
dramatic in the enterobactin-deficient mutant, UTI89ΔentB. (b) In the iron-poor growth media
RPMI, which is more chemically rich than M63, wild-type UTI89 is inhibited by SCN treatment
alone, likely due to enterobactin sequestration as previously published. Additional ligands have
mixed effects, slightly promoting or restricting growth. In contrast to wild-type UTI89,
enterobactin-deficient UTI89ΔentB is significantly inhibited by combined SCN and ligand
treatment. Notably, this strain is not inhibited by SCN alone (water condition), demonstrating
113

that enterobactin sequestration is not part of the antimicrobial mechanism in this strain. Cultures
were grown at 37°C for 20 hours and plated for cfu enumeration; bars indicate the mean ± SD of
at least three independent cultures. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; oneway ANOVA compared to water addition control.
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Figure 6. Pyrogallol concentrations are significantly correlated with SCN’s activity. Molar
concentrations of pyrogallol were measured in whole urine following urease treatment. Urines
were spiked with the exometabolite 4-fluorosalicylic acid (4FSA) and peak area ratios were
compared to standard curves prepared with pure standard and 4FSA. We compared permissive
(P, blue boxes) and restrictive (R, red boxes) urines; pyrogallol was found to be significantly (p
= 0.0007, Mann Whitney test) elevated in restrictive samples (a), and was also significantly (p <
0.0001, Spearman correlation) correlated with increasing SCN activity (b).
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Figure 7. SCN binds heterogeneous ligand complexes. (a) Native FTICR mass spectrometry
detects the +9 charge state of SCN with an observed mass of 20674.8 ± 5.1 Da (20675 Da
calculated from sequence). Mixing SCN with the urinary ligand pyrogallol or with caffeic acid
yields new peaks that correspond to the mass of a 2:1 ligand:iron complex (peaks 2 and 3), while
a non-binding control, salicylic acid, does not result in new peaks. Incubating SCN with a
mixture of three urinary ligands produces a distinct peak at a mass corresponding to a
[Fe(pyrogallol)(caffeic acid)]1- complex (peak 4). (b) Native MS detects SCN’s +8 charge state
using nano-spray ESI coupled QTOF. The theoretical protein mass closely matches the mass
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observed at 20673.5 ± 3.1 Da (top plot). A +60 secondary peak was also consistently detected.
When mixed with Fe(III) and the ligands catechol and 2,3-dihydroxybenzoic acid (60 µM,
bottom plot), several mixed ligands species are detected as noted (peaks 3-6), the two most
prominent of which (peaks 5 and 6) feature three non-identical ligands chelated to an iron atom.
These results confirm that SCN does indeed bind heterogeneous complexes and suggests that
these complexes may be preferentially bound over homogeneous complexes.
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CHAPTER THREE: SUPPLEMENTARY FIGURES
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Supplementary Figure 1. DSF screen identifies fractions with SCN-binding profiles. HPLC
fractions from four solid-phase elutions were individually tested for SCN binding by DSF.
Fractions were reconstituted in water and mixed with 3 µM SCN in PBS with or without an
additional 20 µM iron as indicated. Plots are divided into subgroups of sequential fractions for
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visibility. Pooled restrictive (left column of panel) or permissive (right column of panel) urines
(four urines each) were fractionated over Chrom P SPE and collected as the flow-through (a,b),
water wash (c,d), 50% methanol elution (e,f), and 100% methanol elution (g,h). DSF was
performed as described in the methods; plots are shown as the first derivative of the fluorescence
signal. In each plot, SCN protein alone is shown as a red line for comparison.
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Supplementary Figure 2. A urinary metabolite that does not bind SCN also does not
potentiate its antimicrobial activity in defined M63 media. UTI89 and its enterobactindeficient mutant were grown for 20 hours with or without 5 µM t-ferulic acid, a candidate
identified in the restrictive fractions but shown not to bind SCN by DSF and fluorescence
quenching. Compared to PBS control, 1.5 µM SCN does not restrict bacterial growth in the
presence of this metabolite. Bars represent three independent cultures, shown as mean ± S.D.
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Supplementary Figure 3. Equimolar pyrogallol synergizes with SCN to restrict
uropathogen growth. In M63 minimal media, 1.5 µM pyrogallol in combination with 1.5 µM
SCN limits wild-type UTI89 and UTIΔentB growth compared to control PBS treatment. Media
was inoculated with 103 cfu/mL of the indicated strain and grown for 20 hours before plating for
viable cfu. Bars represent the mean ± SD of three independent cultures. * p < 0.05, one-way
ANOVA with multiple comparisons.
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Supplementary Figure 4. Rich media (LB) does not support SCN activity, with or without
supplemented catechol. UTI89 wild type and entB mutant were grown in rich LB media for 20
hours with 1.5 µM SCN or equivalent volume PBS (grey bars). Media was then supplemented
with 5 µM catechol and re-tested for SCN activity (black bars). In contrast to the minimal media
tested, LB does not support SCN’s antimicrobial activity, even when supplemented with relevant
catechol concentrations. Bars represent three independent cultures, shown as mean ± S.D.
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Supplementary Figure 5. Free urinary pyrogallol concentration is correlated with urinary
sulfated pyrogallol. Elevated molar concentrations of pyrogallol are significantly correlated
with relative abundance measured previously for sulfated pyrogallol. Data points represent data
from a single donor urine specimen. p < 0.0001, Pearson correlation; Linear regression of logtransformed values (red line) yields r = 0.74 and slope = 0.9337.
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Supplemental Figure 6. Urinary ligand quantification. Urinary concentrations of several free
aryl alcohols were determined by GC-MS in a set of 28 healthy donor urines. Urines were spiked
with 4FSA, urease treated, and derivatized for GC-MS. Ligand concentrations were determined
from peak areas using standard curves developed with 4FSA for each ligand. Peak height was
used for 4-methylcatechol (c) because of poor baseline resolution between closely neighboring
peaks. Here, caffeic acid (b) approaches statistical significance (p = 0.06), while other ligands
catechol (a), 4-methylcatechol (c), and 3,4-dihydroxyhydrocinnamic acid (d) do not appear to
significantly distinguish these phenotypes in this urine set. Sets were compared for significance
by the Mann Whitney test.
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Supplementary Figure 7. Highly restrictive urines have improved correlation with urinary
ligand concentrations. Samples with SCN activity greater than log 3 were previously identified
as particularly associated with aryl metabolome signatures. We compared SCN ligand
concentrations by GC-MS in highly restrictive (hR, red boxes) vs. permissive urines (P, blue
boxes). Here, pyrogallol (a), catechol (b), and caffeic acid (c) more significantly distinguish
highly restrictive from permissive urines, consistent with a higher aryl ligand association in these
urines. (d) 4-methylcatechol and 3,4-dihydroxyhydrocinnamic acid (e) are less consistently
associated with restrictive or permissive urines.
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Supplementary Figure 8. Salicylic acid does not affect SCN melting in DSF. SCN was mixed
with iron and salicylic acid and melted as described above. Fluorescence signal of the SYPRO
dye was monitored on the HEX channel, and is plotted as the first derivative with respect to
temperature.
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CHAPTER THREE: TABLES
Table 1. Characteristics and parameters of pooled restrictive and permissive urines.
restrictive
permissive
parameter
p-value
(mean ± SD)
(mean ± SD)
age
36 ± 9.35
34 ± 6.73
0.7402
pH
specific gravity
SCN activitya
a

6.87 ± 0.24

5.74 ± 0.61

0.0136

1.016 ± 0.014

1.008 ± 0.003

0.3033

7.00 ± 1.79

-0.05 ± 0.13

0.0002

SCN activity is described in reference 19.
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Supplementary Table 1. GC-MS metabolomics identifies candidate ligands enriched in
DSF-positive fractions.
restrictive vs.
retention
permissive
standard
metabolite GC-MS identification
time
(approx. peak
obtained
height ratio)
a-hydroxyphenylacetic acid
11.1
2.3
pyrogallol

11.9

16

yes

4-hydroxyphenylacetic acid

13.1

1.5

yes

3-hydroxyphenylacetic acid

12.7

1.3

-

13

1.5

yes

furoylglycine

13.4

7.7

yes

dihydroxy benzyl alcohol

13.7

R only

-

3-methoxy-4-hydroxybenzoic acid

14.5

8.9

-

3-(3-hydroxyphenyl)-3-hydroxypropanoic acid

15.5

33.1

-

3,4-dihydroxyhydrocinnamic acid

16.4

14.7

yes

caffeic acid

18.9

R only

yes

4-hydroxyhippuric acid

19.1

2.4

-

t-ferulic acid

17.7

11

yes

propyl gallate

17.2

16.7

yes

indole-3-acetic acid

16.6

20.3

-

methylcatechol

10

1.0

yes

5-hydroxyindole

13.3

P only

yes

4-hydroxybenzaldehyde

9.92

R only

yes

3-hydroxybenzoic acid
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CHAPTER FOUR

Conclusions, Implications, and Prospects
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4.1 Summary of the Thesis
This thesis describes how Escherichia coli urinary tract colonization is influenced by urine
composition. During urinary tract infection (UTI), uropathogens and host cells modify urine and
urine-exposed bladder surfaces with metal binding siderophores and the soluble siderophorebinding protein siderocalin (SCN), respectively (1–3). We investigated these agents’ effects on
uropathogenic E. coli (UPEC) growth in individual urine specimens from a healthy reference
population. In a subgroup of individuals, we observed enterobactin expression to be a key factor
permitting UPEC growth in SCN-supplemented human urine. Because SCN neutralizes
enterobactin in non-urinary experimental systems, this result speaks to a distinctive role for
urine-specific components. To determine the mechanism behind these individual differences, we
compared individual specimens using microbiological and biochemical techniques. This
multifaceted approach resolved a metabolomic signature associated with SCN antimicrobial
activity, highlighting aryl alcohols and catecholates in the context of relatively alkaline urine pH.
We further demonstrated that these catecholate urinary metabolites (Fig. 1a,b) participate in iron
sequestration by acting as ferric cofactors of SCN (Fig. 1c). Biophysical screens on human
specimens identified urine fractions enriched in certain catecholate ligands that were correlated
with increased antimicrobial SCN activity. We then used quantitative mass spectrometry to
determine the identity and concentrations of key metabolites responsible for the observed
antimicrobial activity, and demonstrated that these cofactors could promote SCN activity when
added to an iron-limited defined media condition.
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These results support a model in which the urinary metabolome is able to control urinary tract
colonization by pathogens, as summarized in Figure 2. Diet-derived factors (Fig. 2a) include
metabolites (Fig. 2b) that can chelate iron in the urine (Fig. 2c). During UTI, SCN is elevated in
the urine (Fig. 2b) and sequesters iron in ferric complexes with catecholate urinary ligands (Fig.
2d). These interactions prevent iron acquisition by UPEC, which require the siderophore
enterobactin to efficiently obtain iron and grow (Fig. 2e). SCN’s activity can also therefore be
potentiated using drugs that block enterobactin biosynthesis, such as 2,3-DHB-AMS (Fig. 2e)
(1). The human metabolome may thus represent an unappreciated contributor to UTI
susceptibility and pathogen evolution. Overall, this work suggests dietary and physiologic
determinants of UTI susceptibility in human populations.

4.2 Therapeutic Implications and Prospects
Since adult females experience UTI at much greater frequency than males (4), we hypothesized
that perhaps female urine would be more permissive for UPEC growth (1). Categorically, a slight
majority of female urines were permissive (65%) while male urines were equally distributed
between permissive and restrictive, though this difference was not statistically significant. To test
whether the degree of inhibition was correlated with sex, we compared the SCN activity of male
restrictive vs. female restrictive urines (1). Male urine was indeed more restrictive than female (p
= 0.0405, Fig. 3), though due to the small sample numbers (12 male, 9 female), this warrants
evaluation on a larger data set. This trend is consistent with UTI’s adult female predilection, and
if validated more broadly, poses interesting and unexplored hypotheses about basic susceptibility
differences. While the female anatomy is generally blamed for women’s increased UTI
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frequency (4, 5), sex-linked patterns in urinary composition would be a useful, but currently
unappreciated factor for providers and patients alike: while anatomy is biologically rigid and
intractable, urinary chemistry manipulations, as this thesis has suggested, are readily achievable
and could represent a promising paradigmatic focus for future UTI control.

The aryl alcohol metabolites identified by these studies are known byproducts of human and
commensal metabolism, derived largely from dietary plant sources such as berries, tea, and
coffee (6–10). This raises an interesting question about the efficacy of cranberry products in
popular use for preventing UTI. The literature on cranberries and UTI is vast, and although some
studies show small protective effects, a recent meta-analysis concluded there was little to no
evidence that cranberry products prevent community-acquired UTI (11). A recent double blind
and placebo-controlled study in the USA showed no reduction in recurrent UTI in the cranberry
patient group (12), while in a separate study, cranberry capsules significantly reduced the rate of
UTI following elective gynecologic surgery (13).

This thesis, however, suggests alternative interpretations and directions for these studies. First,
our results show that individual variability dominates antimicrobial responses in the urine;
because of this, conclusions across an uncontrolled cohort will be inherently challenging.
Second, while metabolites derived from cranberry consumption may be relevant and capable of
restricting iron, as suggested by in vitro studies (14, 15), consuming effective quantities of
cranberry juice also may lower the urinary pH. We have shown that acidic pH prevents cofactor-
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mediated iron sequestration by SCN (1). Pairing cranberry, or other phenolic-rich dietary
supplements, with urinary alkalinizing agents may enhance their protective effect.

Third, these cranberry products, much like antibiotics, may also be selecting for particular
pathogens, as discussed below. Barbosa-Cesnick et al. tracked the bacterial species causing the
index and recurrent UTI cases in their cohort, and although cranberry products did not reduce the
frequency of recurrent UTI, the pathogen profile was slightly altered, in regard to the frequency
of Enterobacteriaceae (12). Work in this thesis suggests that enterobactin is uniquely suited to
acquiring iron in urines with a restrictive composition (1). If the etiologic species presented by
the authors are divided into enterobactin-producers and non-producers (Table 1), a Fisher’s exact
test concludes that recurrent infections in the cranberry cohort are significantly associated with
enterobactin producers vs. non-producers (p = 0.02); this association was not present at
enrollment (p = 0.45). This correlation is consistent with the results of this thesis, and further
argues for targeting enterobactin biosynthesis as part of an individualized UTI prophylactic
regimen.

While many of the metabolites identified in this thesis may begin as plant-derived compounds,
the process by which they are catabolized before being excreted in the urine could very well play
an important role in UTI control. Microorganisms in the human intestine may extensively
metabolize polyphenolic precursors, and studies in germ-free mice have shown significantly
reduced aryl sulfate complexity in the absence of a conventional gut microbiome (7, 16, 17). One
might therefore reasonably hypothesize that dietary control alone will not produce uniform
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results in a heterogeneous cohort. Known variations in the activity and expression of metabolitemodifying enzymes such as human liver sulfotransferases and catechol-O-methyltransferases
could also impact aryl metabolite conjugation and speciation in the urine (18–21). Although
causal evidence linking specific microbes or specific genetic traits with urinary metabolites is
sparse, microbiome and human genome studies indicate that such connections in human
metabolism may one day be feasible (7, 16, 22–24). Extending these discoveries to the clinic
could manifest as an individualized therapy involving particular diet and microbial
manipulations as necessary to support a restrictive urinary environment. Metabolomic
correlations, such as those presented in this thesis, also provide an example of how relatively
rapid mass spectrometry analyses could identify patients who could benefit from this therapy,
and may guide efforts to sustain unfavorable (i.e. restrictive) growth conditions in individuals
prone to recurrent UTI. Understanding the restrictive mechanism in humans more completely
will further aid our ability to predict susceptibility and outcomes in UTI, and provide a
biochemical roadmap to support potential clinically relevant interventions based on controlling
urinary composition.

4.3 Perspectives on E. coli Iron Acquisition in Human Urine
The data presented in this thesis also present a curious and unique role for the conserved
siderophore enterobactin in resisting SCN inhibition during urinary growth. The previous dogma
surrounding SCN and enterobactin was that the former made the latter essentially useless to the
pathogen, thus motivating pathogen evolution towards additional “stealth” siderophores (25–27).
Our model does not exclude this arrangement in other infection contexts, including other urinary
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tract niches. Rather, we present additional evidence that multiple siderophores are useful to
pathogens because they provide tailored, distinct advantages to the diverse microenvironments
encountered during infection (3, 28, 29). Our data suggest that in restrictive individuals,
enterobactin biosynthesis is critical for the pathogen to acquire urinary iron in the presence of
SCN (1). This provides a possible explanation for the ubiquitous expression of enterobactin
observed to date in E. coli and K. pneumoniae UTI isolates (2, 30) (and unpublished data).
Ongoing work is exploring the role of enterobactin and its biosynthetic precursors in UPEC
pathogenesis, with a focus on in vivo relevance. We hypothesize that enterobactin is critical
because of its superior iron affinity relative to other siderophores—particularly at elevated pH—
and because its chemical likeness to the aryl metabolites may enable it to more effectively
compete with the SCN cofactors for iron coordination and eventual release (31–33). It is also
possible that at some point during bacterial growth, enterobactin production outmatches local
SCN concentrations and thus iron sequestration by SCN no longer offers a stoichiometrically
meaningful antimicrobial response.

Our findings provide support and context to existing models of the early innate immune response
to E. coli cystitis. During early experimental murine cystitis, both host SCN and E. coli
enterobactin biosynthetic genes are upregulated within the bladder epithelium (34–37). In this
thesis we showed that SCN levels in the human urinary tract were elevated in a stereotypical
uncomplicated E. coli cystitis population (1). The baseline urinary metabolomic profiles
determined here would be present during early UTI pathogenesis. These results suggest that SCN
can act against UPEC in the bladder before ascension to the kidney parenchyma or blood, which
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may trigger additional responses from renal alpha intercalated cells (36). If human alpha
intercalated cells acidify urine in response to bacterial products as described in mice, current
results indicate that this would diminish SCN’s antibacterial activity (1). Acidification could
correspond to a strategic shift away from SCN to control bacterial growth or to introduce
additional innate defense factors that render SCN more active at lower pH. It is also possible that
acidification may be part of a preemptive response to limit the systemic acidosis associated with
Gram-negative sepsis. Further observational or interventional studies may be able to reconcile
these events.

Associating individual factors with disease susceptibility or therapeutic options is of
considerable interest. Precision medicine has provided immeasurable benefits to the fields of
cancer treatment and diagnosis (38–42), and as antibiotic options for bacterial infections become
increasingly limited, patient stratification and virulence-targeted, patient-matched therapies are
of ever-increasing importance (4, 43–45). UTI is the second most common reason for antibiotic
prescription, and would particularly benefit from new therapies and reduced antibiotic failure
rates (5). This thesis highlights the only iron acquisition pathway present in all known UPEC and
urinary Klebsiella isolates, the siderophore enterobactin, as a virulence target that synergizes
with host immunity (1). A drug similar to 2,3-DHB-AMS, which abrogates enterobactin
production and potentiates SCN activity in urine (1, 46), is now attractive for controlling
recurrent UTI without the extensive collateral damage to the patient’s commensal microbiota
typical of traditional antibiotics (47–49). Our results further suggest that dietary manipulations
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and urinary alkalinization may be well-tolerated, non-pharmaceutical approaches to creating a
urinary environment unfavorable to bacterial colonization.

4.4 Methodology Developments and Applications
Finally, the methodologies developed in this thesis are useful and applicable in research fields
well beyond UTI and bacterial pathogenesis. Our growth assay makes use of human biological
specimens and allows chemical manipulations that are difficult in humans, without resorting to
animal models. The viable cfu endpoint is also critical, in that it is several orders of magnitude
more sensitive than optical density readings, and allows the assay to begin with a small
inoculum. This likely better represents a host’s encounter with a given pathogen than a superphysiological experimental bolus, as is often required to observe a phenotype in experimental
murine models. These assays also enabled us to focus on differences between individuals using
human specimens. Most previous studies of urinary growth were performed on pooled urine
specimens or a single sample (30, 36). Investigating the natural factors that make a human host
more or less susceptible to infection precludes the experimental bias of inserting non-physiologic
changes such as host species, genetic, or chemical manipulations. Instead, we identified key
players native to human specimens.

Human sample exploration also permitted us to develop a multi-step biophysical screen for
urinary SCN ligands. Unlike previous studies (32), this approach uses human urine that is
chemically fractionated to improve sensitivity and downstream mass spectrometry. This method
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could be optimized for other samples such as serum, saliva, or cerebrospinal fluid to identify
protein-ligand interactions, or for more robust and sensitive small molecule chemical analyses.

Mass spectrometry’s role in biomedical inquiry has grown recently as metadata and multi-omics
approaches become more tractable and common (50, 51). Our urinary metabolomic approach (1,
52) capitalizes on both untargeted and targeted mass spectrometry, using the former to highlight
patterns that are validated by quantitative targeted analyses. By identifying chemical patterns,
such as the aryl sulfates in this thesis, one is able to bootstrap protocols that amplify an
instrument’s analytical power (53). Those wary of conclusions drawn from untargeted,
multivariate dataset can then validate results on the same platform and also by orthogonal
techniques. As large datasets become more common, these reductionist validation strategies will
become more critical when drawing inferences from spectral studies.

Lastly, this thesis presents a novel approach to understanding degenerate small molecule ligand
binding. We hypothesized that as a non-symmetric tripartite binding site, the SCN calyx could
bind mixtures of urinary ligands with varying levels of preference. This hypothesis is difficult to
test by X-ray crystallography and NMR, as signals in these techniques are population averages
and cannot adequately resolve heterogeneous ligand occupancy. By using non-denaturing, or
native, mass spectrometry to detect the mass of non-covalent complexes (54, 55), we were able
to resolve heterogeneous ferric-ligand mixtures bound to SCN, since the ligand mixtures possess
unique total masses. This demonstrates for the first time that human urinary ligands can occupy
the SCN calyx in an assortment of permutations. Our results suggest that these combinations
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may even be the preferred ligands in a mixed environment. This discovery underlines the
importance of investigating biological processes in a relevant context; our results suggest that the
idiosyncratic ligand combinations possible in vivo are vast and biologically relevant, and highly
variable between individuals. Appreciating such subtle biochemical differences that could affect
human health will be necessary to fully understand and effectively address the full spectrum of
human disease.

4.5 Closing Remarks
The findings in this thesis show the importance of the host biochemical context in understanding
particular host-pathogen interactions. We show that urinary chemical composition varies
significantly between individuals, and this has dramatic and causal effects on an important
antimicrobial protein’s activity (1). Compositional differences are also shown to affect the
pathogen’s metabolic needs, requiring the siderophore enterobactin for efficient iron acquisition
in this context. These findings describe a novel relationship between the antimicrobial protein
siderocalin and bacterial siderophores, distinct from that described in other infection models,
further arguing for chemically distinct siderophores’ environment-specific and niche-adapted
roles (3, 28, 29, 56, 57). These individual differences led us to identify characteristic metabolites
(Fig. 1) that control SCN’s activity and can prevent uropathogen growth. Together, this thesis
presents a new paradigm for pathogen iron acquisition in urine (Fig. 2), and strongly supports
therapeutic urinary composition manipulation as a personalized, non-antibiotic alternative to
controlling UTI incidence in susceptible populations. As concerns mount about an impending
post-antibiotic era (58), developing truly novel antimicrobial therapies is an unequivocal public
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health imperative. This thesis indicates that analyzing human specimens and observing how
individuals respond to particular infections may illuminate new directions for the treatment of
numerous infectious diseases.
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CHAPTER FOUR: FIGURES

Figure 1. Aryl alcohols make up the set of SCN ligands that contribute to its antimicrobial
activity in urine. (a) Highlighted urinary metabolites that bind SCN as ferric cofactors. These
ligands share obvious structural similarity with each other, and with the bacterial siderophore
enterobactin (b). When deprotonated, the catecholate moiety is capable of coordinating an Fe(III)
ion (c); the resulting triscatecholate complex’s negative charge, delocalized over the aromatic
complex, helps make these aryl cofactors highly stable occupants of the positively charged SCN
calyx.
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Figure 2. Diet-derived urinary metabolites promote SCN iron sequestration and
antimicrobial activity. The data presented in this thesis supports a model in which consuming
certain plant-based foods and beverages (a) establishes an aryl alcohol-enriched urinary
metabolome (b) that is likely the product of host and microbiome metabolic processes. In the
urine, certain catecholate metabolites are able to participate in iron chelation (c). When UPEC
enter the bladder, upregulated SCN helps further drive pH-dependent ferric complex formation
with aryl cofactors (d), aiding the immune response in restricting pathogen iron access. Our data
suggests that in this infection context, the UPEC siderophore enterobactin is necessary to
efficiently acquire iron (e). This demonstrates that drugs targeting enterobactin pathways (like
2,3-DHB-AMS) may be promising therapeutic leads, and may synergize with diet and pH
manipulations.
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Figure 3. Among restrictive urine specimens, males exhibit higher SCN activity levels than
females. SCN antimicrobial activity was measured as previously described in individual donor
urine specimens. Those termed restrictive (SCN activity > 1; n = 21) were compared by the
donors’ reported sex. Here, males showed a significant tendency toward higher levels of SCN
activity. * p = 0.0405, Mann-Whitney test.
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CHAPTER FOUR: TABLES

Table 1. Cranberry products may select for enterobactin-producing uropathogens in
patients experiencing recurrent UTI (adapted from reference 12).
first infectiona
Ent+ strainsb Ent- strains

a
b

first recurrencea
Ent+ strains

Ent- strains

cranberry

130

36

28

3

placebo

135

46

15

9

First infection, p = 0.45; first recurrence, p = 0.02; Fisher’s exact test.
Enterobactin positive vs. negative based on bacterial species identified from patient urine

specimens. All E. coli and K. pneumoniae isolates were assumed to produce enterobactin,
consistent with published studies and the author’s unpublished observations.
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APPENDIX

Detection and expression studies on uropathogenic
Escherichia coli siderophores.
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BACKGROUND
Uropathogenic Escherichia coli (UPEC), the most common pathogen associated with urinary
tract infections (UTIs) (1), synthesizes and secretes small molecular weight chelators called
siderophores to acquire essential iron during infection (2–4). Since host innate immune factors
extensively sequester available iron, siderophore expression is widely considered a critical
virulence adaptation for UPEC and many other human pathogens (4–7). Evidence supporting this
conclusion includes siderophore mutants’ attenuated virulence in animal models, identification
of biosynthesis genes under positive selection, and transcriptomic datasets showing significantly
upregulated siderophore gene expression during murine infection, during growth in normal
human urine ex vivo, and in RNA isolated from cystitis patients’ urine (8–12). Specifically
measuring complete siderophore production in these environments, however, requires sensitive
analytical techniques even under ideal, controlled conditions. As a result, bona fide siderophore
production during UTI is poorly understood.

Bacterial pathogens often possess the biosynthetic machinery to make multiple siderophores.
These seemingly redundant efforts are thought to provide particular advantages in specific host
contexts, and to bind metals for both nutrient acquisition and defense against host-driven toxic
assaults (3, 13–15). All known UPEC isolates produce the catecholate siderophore enterobactin,
and strains may also possess the pathways for salmochelin, yersiniabactin, and aerobactin (2).
Because genetic assays like PCR are rapid, straightforward, and widely available, a UPEC
strain’s siderophore arsenal is generally assessed by the presence of one gene in each pathway
(16). However, this assignment can be misleading: genotype positivity does not equivocally
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predict siderophore production. A notable example is the well-studied pyelonephritis isolate
CFT073, which has the common yersiniabactin marker gene fyuA but does not produce
yersiniabactin when grown in iron-limiting media (2). To identify these discrepancies,
siderophore products must be measured. Without these data, comparisons among strains and
explanations for virulence may be incomplete and misrepresented.

Addressing these shortcomings requires optimization in analytical siderophore detection. Here,
we describe improvements in methods for detecting the siderophores enterobactin, salmochelin,
and aerobactin by liquid chromatography-mass spectrometry (LC-MS). For enterobactin and
aerobactin, we present an improved MRM scheme for detecting each siderophore with greater
sensitivity and specificity. These methods are then applied to demonstrate their utility in human
clinical sample analysis, detecting chemical modifications, and developing true siderophore
production profiles for clinical isolates. Together, these data exhibit the potential gains in
knowledge from sensitive siderophore detection, and provide tools to more accurately understand
host-pathogen interactions during human UTI.
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EXPERIMENTAL PROCEDURES
Bacterial strains. For method development, we used the well-characterized clinical isolates
UTI89 and CFT073. Cultures were grown from a single colony in LB for 4-6 hours before
diluting 1:1000 into M63 minimal media and incubating at 37°C overnight. After centrifuging
for 10 min at 7,700 rpm, supernatants were either filtered through 0.2 µm syringe filters, or
extracted on DEAE solid phase extraction (SPE) as previously described (2).

For aerobactin screening, iucD-positive clinical isolates were obtained from a previous study of
E. coli bacteriuria at Barnes Jewish Hospital in St. Louis, Missouri that is described elsewhere
(17). Strains were genotyped by dot-blot hybridization at the Molecular and Clinical
Epidemiology Laboratory at the School of Public Health, University of Michigan, Ann Arbor.
All studies were approved by institutional review boards at Washington University School of
Medicine and the University of Michigan.

Human urine specimens. Human urines specimens were collected from patients presenting to an
outpatient clinic with uncomplicated E. coli cystitis at the University of Washington, Seattle,
WA, as described elsewhere (18). Here, frozen urine specimens were thawed on ice, centrifuged,
then 100 µL internal standard was added to 900 µL urine. After 0.2 µM filtration, samples were
diluted 1:1 with water and promptly analyzed by LC-MS-MRM. For controls, healthy urine
specimens were obtained from volunteers at Washington University School of Medicine and
prepared identically. All participants provided informed consent and studies were approved by
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institutional review boards at the University of Washington and Washington University School
of Medicine.

Enterobactin halogenation. To test enterobactin oxidation, we used a purified components
system to monitor enterobactin halogenation by LC-MS. Enterobactin was purified by HPLC
from UTI89ΔiroA/ybtS as described previously (18). Reagent NaOCl (Sigma) was checked for
hypochlorite concentration by UV spectroscopy at ε292 = 350 M-1cm-1 (19). Enterobactin (500
µM) was mixed with various molar ratios of NaOCl (from 5µM to 5mM) as indicated and
incubated at 37°C for 1 hour. Reactions were analyzed by LC-MS in negative ion full scan
(EMS) mode and peaks were compared to calculated masses for chlorinated enterobactin
products.

Liquid chromatography-mass spectrometry. LC-MS studies were performed on a Shimadzu
Prominence LC-20 XR UFLC-coupled AB Sciex QTRAP 4000 hybrid triple-quadrupole/linear
ion trap instrument. Chromatography was achieved on an Ascentis Express phenyl-hexyl column
(100 x 2.1 mm, 2.7 µm; Supelco, Sigma) over a gradient of 0.1% formic acid (Fluka, Sigma) to
90% acetonitrile (EMD Millipore) + 0.1% formic acid. Full-scan experiments used the enhanced
MS (EMS) mode, scanning from m/z 100 to 1400 at scan speed of 1000 Da/s. The IonSpray
voltage was 4,500 V in positive mode and -4,500 V in negative mode. Curtain gas and source
temperature were 10 units and 500°C, respectively. The declustering potential was set to 110 or 110 V, and collision energy was set to 5 or -5 V. Tandem MS experiments were carried out in
enhanced product ion (EPI) mode using collision-activated dissociation (CAD). The declustering
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potential, entrance potential, and collision exit cell potential were set to 110, 10, and 12 V,
respectively (-110, -10, and -12 V for negative mode). For siderophore detection and
quantification experiments, multiple reaction monitoring (MRM) methods were used to monitor
transitions as detailed in Table 1. Spectra were visually evaluated and peak areas were measured
with Analyst version 1.5.1 (AB Sciex).

Table 1. MRM transitions for siderophore ions in positive and negative mode.
analyte

Q1

Q3

collision energy (V)

linear enterobactin

688

447, 224

13

718

467, 234

35
35

cyclic enterobactin

670

447, 224

35

13

700

467, 234

35

aerobactin

565

547

35

13

587

569

35

linear enterobactin

686

445, 222

-40

13

716

465, 232

-40

cyclic enterobactin

668

445, 222

-40

13

698

465, 232

-40

aerobactin

563

527, 483, 297

-25, -35, -39

13

585

504, 381, 310

-35, -40, -39

positive mode

C linear enterobactin
C cyclic enterobactin
C aerobactin

negative mode

C linear enterobactin
C cyclic enterobactin
C aerobactin
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RESULTS AND DISCUSSION
Enterobactin and salmochelin have improved signal in negative ion ESI.
Siderophore detection has largely relied on LC-MS approaches because of the siderophores’
relatively large masses and the advantage of analyzing aqueous samples with minimal
preparation by reverse phase chromatography-coupled instruments. For practical and technical
reasons, previously published methods have used positive mode electrospray ionization (+ESI)
(2, 3, 20, 21). However, preliminary work was unable to detect enterobactin or salmochelin in
urine, and detection in supernatants often required chemical extraction to concentrate samples
prior to analysis (unpublished observations and personal communications; Robin Shields-Cutler,
Chia Hung, Jeffrey Henderson). Since technologic advances have improved sensitivity issues for
which negative mode had suffered (22), and the multiple hydroxyl groups on the highly
conjugated enterobactin structure would provide ample sites for deprotonation, we hypothesized
that negative mode could detect enterobactin and salmochelin with greater sensitivity than
positive mode.

Using an AB Sciex hybrid triple-quadrapole/linear ion trap mass spectrometer, we compared
catecholate siderophore detection by positive and negative mode. Figure 1 shows the improved
EMS signal for linear (Fig. 1a) and cyclic enterobactin (Fig. 1b), and salmochelin MGE
(monoglucosylated enterobactin; Fig. 1c). In positive MS/MS, enterobactin and salmochelin
fragmented into detectable ions for a linearized dimer and 2,3-dihydroxybenzoyl-serine
monomer (2). These fragments were also produced in negative mode (data not shown), and
therefore can be used in MRM methods for improved signal to noise. While enterobactin’s signal
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increase in full-scan -EMS appeared somewhat modest in magnitude (Fig. 1a), the difference
became more prominent during MS/MS methods, in particular when analyzing siderophores in
urine. In this context, negative mode MRM was far superior at detecting

13

C-labeled cyclic

enterobactin standard (Fig. 2). These results show that negative mode ESI-LC-MS is a sensitive
approach for detecting catecholate siderophores, and may be preferable for MS/MS-based studies
in complex fluids.

Detecting enterobactin oxidation products by negative mode LC-MS.
During infection, host neutrophils use NADPH oxidase and myeloperoxidase (MPO) to produce
hypochlorous acid (HOCl), which targets a variety of biomolecules and plays an important role
in phagocytes’ ability to kill pathogens (23, 24). Enterobactin, with its catecholate rings, is a
plausible target for halogenation by HOCl. Since neutrophils and other phagocytes are part of the
inflammatory response during UTI (25, 26), we tested whether negative mode LC-MS could
detect enterobactin oxidation products in vitro. Purified linear enterobactin was mixed with
NaOCl and incubated for 1 hour at 37°C. When mixed with a 10-fold excess of NaOCl, native
enterobactin (m/z 686) signal decreased, and this treatment revealed a new peak at m/z 720, and a
small peak at m/z 754-758 (Fig. 3a); these peaks match the expected masses for Cl-ent and Cl2ent. Treating enterobactin with increasing doses of oxidant showed a dose-dependent formation
of the m/z 720 peak (Fig. 3b). Finally, the set of peaks at m/z 720-722 displayed the expected
isotope distribution of a singly-chlorinated enterobactin species (Fig. 3c).
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These results show that enterobactin is a potential oxidation target of neutrophils and other
phagocytes during infection, and that negative ion, LC-MS is capable of detecting these
products. Chlorination most likely occurs on the catechol ring in the activated C5 position,
though this has not been confirmed here. Interestingly, this position is the same location that
glucose is added by IroB in the salmochelin pathway. Lin and colleagues showed that a synthetic
enterobactin brominated at the C5 position prevented glucosylation by IroB in vitro (27). While
further studies are necessary to explore enterobactin oxidation in vivo, this may represent a
serendipitous host defense. It is also unclear what effect halogenation has on enterobactin’s iron
affinity, its recognition by bacterial receptors like FepA, or its sequestration by the innate
immune protein siderocalin. Manipulating these interactions through oxidative modifications
could have significant consequences on pathogenesis in the inflamed bladder, and are worthy of
further biochemical study.

Enterobactin is produced and detectable during human UTI.
To date in the literature, yersiniabactin is the only siderophore shown to be present during human
UTI (3). Since the negative mode enterobactin MRM showed initial promise in urine specimens,
we wanted to know whether we could detect enterobactin in clinical UTI urine specimens.
Recent analyses on RNA preserved from human UTI specimens showed significantly
upregulated enterobactin pathway gene expression (9, 10), but it was unclear whether the
enterobactin product would be stable and abundant to enable detection in frozen urine
supernatants. Using the negative mode MRM as described above with

13

C-labeled internal

standard, we indeed detected linear and cyclic enterobactin in cystitis patient urine (Fig. 4a). Of
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the 15 specimens analyzed, 12 had detectable levels of cyclic and/or linear enterobactin (Fig.
4b). These samples were processed without additional concentration, so it is possible that with
chemical extraction, enterobactin might be detectable in the other three specimens as well.

This finding shows, for the first time, direct evidence that enterobactin is produced at detectable
levels in urine during human UTI. Further studies using calibrated standards could quantify the
enterobactin present. Enterobactin has recently been highlighted as a key UPEC factor allowing
urinary growth in the presence of SCN (18). If enterobactin concentrations greatly exceed those
of SCN in urine, that could provide one explanation for this siderophore’s importance during
UTI. Since this siderophore is the only UPEC siderophore produced by all known UPEC isolates
(2, 4) (unpublished data), detection across a range of clinical samples shows that this product is
indeed synthesized and could play an important role in iron acquisition during human disease.

Optimized aerobactin detection by LC-MS.
Aerobactin is a linear siderophore synthesized from citrate and lysine, and has been correlated
with virulent and often invasive Gram-negative infections (28–30). Typical siderophore
preparations in our lab have used anion exchange on iron-treated minimal media supernatants,
but aerobactin signal was often very low compared to yersiniabactin or enterobactin. Indeed,
internal standards often contained too little or barely enough 13C-aerobactin signal for peak area
comparisons by this method (unpublished observations). We tested aerobactin detection from the
pyelonephritis strain CFT073, using filtered supernatants without prior anion exchange, and
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found that this approach, combined with negative mode LC-MS-MRM, yielded superior
sensitivity (Fig. 5a).

However, higher aerobactin signal brought to our attention a problem: samples without
aerobactin had measurable MRM signal at the

13

13

C

C-labeled aerobactin transition (Fig. 5b). This

co-fragmenting peak could confound quantitative isotope ratios by artificially inflating the

13

C-

aerobactin peak area. Because the difference in mass to the isotope-labeled version is 22 Da, we
hypothesized this represented a persistent sodium adduct that was not dissociated during
MS/MS. Using negative mode EPI, we then fragmented

12

C and

13

C aerobactin under higher

collision energies to identify unique transitions without overlapping masses (Fig 5c). From this,
we identified several transitions for negative mode LC-MS-MRM that offer sensitive and now
specific detection of 12C- or 13C-aerobactin in bacterial supernatants. While the transition m/z 563
> 527 offers the greatest sensitivity for

12

C-aerobactin (Fig. 5d), for the most consistent

comparison to internal standard, the transition pairs m/z 563 > 297 and m/z 585 > 310 for 12C and
13

C aerobactin, respectively, represent the same molecular fragmentation. As a demonstration,

when unlabeled and 13C-labeled CFT073 supernatants are mixed 1:1, these two transitions yield
identical signals on LC-MS-MRM (Fig 5d).

Aerobactin expression patterns revealed by LC-MS.
To study aerobactin expression by UTI clinical isolates, we prepared minimal media
supernatants from 70 isolates that had previously tested positive for the aerobactin biosynthesis
gene iucD (17). Initial siderophore screens were carried out using the prior MRM method in
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positive mode (Fig. 6a). These screens also showed that enterobactin was produced by 70/70
strains (100%) and yersiniabactin by 60/70 (86%). However, because of positive mode’s
limitations, aerobactin was poorly detected in a large subset of samples. We therefore used the
improved negative mode MRM described above to re-evaluate these strains.

Negative mode MRM provides sensitive detection with low background, which aided aerobactin
quantification in these repeated iucD+ strains. Here, expression data naturally groups strains into
three categories of moderate, low, and no aerobactin production—as defined by the positive
control CFT073 and the negative control CFT073ΔiucD (Fig. 6b). Interestingly, these data reveal
a subset of iucD+ isolates which produce no aerobactin under iron limiting conditions. Of the 70
iucD+ strains assessed, 15 (21%) produced no detectable aerobactin by negative or positive
mode MRM. These strains may represent siderophore “cheaters,” strains that possess the
machinery to use certain siderophores without expending the energy required for de novo
synthesis. The large proportion of discordant strains also cautions against using genotype data to
draw conclusions about siderophore expression (16).

In summary, these methodology pursuits have established new standard protocols for sensitive
siderophore detection in the laboratory. As demonstrated here, they are suitable for applications
ranging from biological product discovery to clinical sample investigation. Further work could
aim to improve sample preparation or chromatography and continue to reduce the limits of
detection. Together, they allow a greater understanding of the molecular mechanisms that
determine pathogen iron acquisition during UTI.
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APPENDIX: FIGURES
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Figure 1. Negative mode LC-MS shows improved catecholate siderophore signal. LC-MS
was carried out in Positive and negative ion full-scan EMS with identical HPLC parameters.
Shown are extracted ion chromatograms at the expected negative (-EMS) and positive (+EMS)
ion masses for cyclic enterobactin (a), linear enterobactin (b), and the monoglucosylated
salmochelin (c). The two salmochelin peaks result from different glucose locations along the
linearized molecule (data not shown). Siderophores were HPLC purified from supernatants of
UTI89 grown overnight in M63 minimal media.
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Figure 2. Negative mode LC-MS-MRM detects cyclic enterobactin standards in urine.
Filtered human urine from a single donor was spiked with 13C-labeled internal standard, diluted
1:1 with water, and analyzed by LC-MS-MRM in positive (red) and negative (black) mode. The
MS/MS transitions monitored the same enterobactin fragmentation pattern, but negative mode
yielded superior detection compared to positive mode.
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Figure 3. Enterobactin is sensitive to halogenation in vitro. (a) Purified linear enterobactin
(500 µM) was mixed with water (blue) or 5 mM NaOCl (red) and incubated for 1 hour at 37°C.
Traces are extracted ion chromatograms from negative mode EMS for the expected m/z ranges
indicated: top, linear enterobactin; middle, monochloro-enterobactin; bottom, dichloroenterobactin. (b) Enterobactin (500 µM) was mixed with increasing concentrations (from
bottom, 0, 5, 50, 500, 5000 mM) of NaOCl and incubated and detected as before. (c) Mass
spectrum of the suspected monochloro-enterobactin species is consistent with chlorine’s natural
isotope abundance.
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Figure 4. Enterobactin is produced by UPEC during human UTI. Human uncomplicated E.
coli cystitis samples were spiked 1:10 with 13C-labeled internal standard, then filtered and diluted
1:1 with water before analyzing by negative mode LC-MS-MRM. (a) Linear enterobactin MRM
traces from two representative cystitis urines compared to a healthy control urine and

13

C

standard. (b) Urines from 15 cystitis patients were analyzed as in (a) for linear and cyclic
enterobactin. Bars represent the peak area ratio relative to internal standard. Controls are urines
from healthy individuals, prepared and analyzed identically.
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Figure 5. Improved aerobactin detection sensitivity and specificity in negative ion MRM.
(a) UPEC strain CFT073 was grown overnight in M63 minimal media, centrifuged, and either
extracted with solid phase anion exchange (DEAE) or 0.2 µM filtered. Samples were then run in
negative and positive mode LC-MS-MRM monitoring apo-aerobactin (564 Da). (b)
Representative plot from positive mode MRM showing the aerobactin [M+H]+ at m/z 565>547
and a species at m/z 585>569, the expected mass transition for
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13

C-aerobactin. Similar results

were obtained in negative mode (data not shown). While no 13C-labeled product was added to the
sample, this mass is consistent with the [M+Na+H]+ adduct species. (c) Tandem MS (negative
EPI mode) shows that the m/z 585 species in (b) is indeed not

13

C-aerobactin. These

fragmentation patterns also reveal unique transitions for avoiding species cross-contamination in
MRM. After accounting for 13C mass, the transitions m/z 563>297 and 585>310 were determined
to represent the same molecular fragmentation. Consistent with this assignment, negative mode
MRM peaks from a 1:1 mixture of unlabeled and

13

C-labeled supernatants are nearly identical

for these two transitions (d). Monitoring m/z 563>527, however, yields the greatest sensitivity
and largest 12C-aerobactin peak.

181

Figure 6. Aerobactin expression varies among iucD+ clinical isolates. (a) Aerobactin area
ratios from positive MRM siderophore screen. Supernatants from clinical isolates grown
overnight in M63 minimal media were extracted using DEAE SPE and analyzed directly by LCMS-MRM. Peak areas were normalized to cfu and 13C internal standard peak area. A horizontal
dotted line indicates the level of background signal as defined by iucD negative samples after
normalization to internal standard. (b) Isolates with low or undetectable aerobactin expression in
(a) were reanalyzed using negative mode MRM on filtered supernatants. This method reveals
several low-expressers and a population of iucD+ isolates that do not produce aerobactin (n.d.,
not detected) in low-iron media.
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